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Sans toi, les émotions d’aujourd’hui ne seraient que la peau morte 
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Down syndrome (DS), named after John Langdon Down, is the most common 
chromosomal disorder in man. Down syndrome is caused by trisomy of (parts of) 
chromosome 21.[1] The incidence of Down syndrome in the Netherlands is around 14.6 
per 10,000 live births, which results in around 245 live newborns with Down syndrome 
in the Netherlands each year.[2] Children with DS have distinctive phenotypic facial 
features such as oblique eye fissure, epicanthus, small ears, flat nasal bridge and a 
protruding tongue. 
 In addition to this, DS subjects show generalized hypotonia, short stature and 
mental retardation of variable severity. Around fifty percent has a congenital heart 
defect.[3] Children with DS have multiple ear-nose-throat abnormalities such as 
stenotic ear canals with smaller or abnormally inserted Eustachian tubes, and midfacial 
hypoplasia.[4] DS children also have hyperproduction of mucus and lower respiratory 
tract abnormalities such as laryngo- and tracheomalacia. 
Clinical profile of infections, autoimmune disease and malignancies in DS
Nowadays, the majority of Dutch DS children live at home. They are exposed to the 
same viral and bacterial pathogens and environmental factors as their brothers and 
sisters. However, children with DS are more frequently ill.[5] They are more prone to 
respiratory tract infections. This is at least partly explained by a combination of their 
phenotypical facial features and their anatomical respiratory tract abnormalities 
together with generalized hypotonia. Complications of respiratory tract infections 
remain the most important cause of mortality in all age groups in DS.[6-10] DS 
children also show more haematological malignancies and autoimmune phenomena 
such as celiac disease, thyroid disease and diabetes mellitus.[11-15] Leukemia (both 
acute lymphoid and myeloid) and leukemoid reactions show an increased incidence in 
Down syndrome; estimates of the relative risk are 10-20x higher compared to the 
non-DS population.[11, 12, 16] Statistics on bacterial sepsis show higher morbidity and 
mortality figures in DS children.[6, 17] This combination of increased incidence of 
infections, autoimmune diseases and haematological malignancies has led to the 
hypothesis of an altered adaptive immune system in Down syndrome. 
 Several theories have been postulated. During corrective heart surgery it was 
noted that the DS thymus looked different compared to non-DS thymuses.[18-22] As a 
result, immunological research in DS focused on T-cell problems for decades. The 
clinical profile of recurrent infections, autoimmune diseases and malignancies in 
combination with a higher incidence of Alzheimer-like disease in relatively young DS 
adults led to the hypothesis of premature ageing or ‘immunosenescence’ of thymus 
and T-lymphocytes.[22-24] But the question remains: is that true? This thesis provides 
more in depth research - both quantitative and qualitative - on the alterations in the 
adaptive immune system in children with Down syndrome. 
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The adaptive immune system: basic background
The key players in the adaptive immune response are T- and B-lymphocytes. Both T- and 
B-lymphocyte precursors are generated from haematopoietic stem cells in the bone 
marrow. A unique B-cell antigen receptor is created and expressed on the membrane 
through gene rearrangements without previous antigen-exposure. While B-lymphocytes 
fully develop in the bone marrow, immature T-cell-precursors migrate to the thymus. 
Within the thymus, T-cell-precursors can only survive when their T-cell receptors can 
interact with self major histocompatibility complexes (MHC) expressed on cell membranes. 
Thymocytes binding to MHC-class I differentiate into cytotoxic-T-lymphocytes (Tc), 
thymocytes binding to MHC-class II differentiate into helper-T-lymphocytes (Th). 
 Naive Th-, Tc- and B-lymphocytes migrate to the secondary lymphoid organs (e.g. 
spleen, lymph nodes, gut- and mucosa-associated lymphoid tissue respectively GALT 
and MALT), and proliferate and differentiate into multiple different effector and 
memory subpopulations after antigen exposure. 
 B-lymphocytes react directly to antigen exposure by producing immunoglobulins 
(Igs). Extracellular pathogens such as bacteria are the main target of these Igs 
(humoral response).
 Tc interact with antigen presented on MHC-class I molecules, which almost all 
human cells express, and can act directly as “killing machines”. Tc are specifically 
suited for strong cellular immune responses against tumour cells and intracellular 
pathogens such as viruses. 
 Th can only interact with antigen-presenting cells (APCs) expressing MHC-class II 
molecules. Examples of APCs are B-lymphocytes, dendritic cells and phagocytes. 
 Th are responsible for coordination and communication with both innate and 
adaptive immune cells; in that sense they serve as immunoregulators. Th can help 
both humoral and cellular immune responses. 
Lymphocyte distribution in the human body
Flow cytometric analysis using specific cell surface (cluster of differentiation, CD) 
markers can differentiate between the various naive and memory B- and T-lymphocyte 
subpopulations in peripheral blood. However, peripheral blood lymphocytes only 
represent around 2% of the total number of lymphocytes in the human body.[25] 
Lymphocytes continuously circulate through the body and migrate to their preferred 
sites situated in primary and secondary lymphoid organs. The majority of lymphocytes 
actually reside in the secondary lymphoid organs, especially in the lymph nodes 
(estimated 40% of total lymphocytes). So, by analysing peripheral blood, only a minor 
fraction of the lymphocyte population can be visualized (Figure 1). Therefore, conclusions 













Also, the distribution of lymphocytes can vary between individuals and groups.[26, 27] 
For instance in Down syndrome, an increased genetic expression of lymphocyte 
homing receptors and cell adhesion molecules is found in thymic epithelium and 
thymocytes, potentially leading to an inefficient release of T-lymphocytes into the 
peripheral blood and thereby alteration of the distribution of T-lymphocytes in the 
body. Moreover, the results of one specific blood analysis do not necessarily reflect a 
permanent difference, as many factors – e.g. recently encountered antigens – can 
strongly influence the amount of lymphocytes circulating in the blood.[27] Exposure 
to pathogens can also leave a personalised fingerprint, which shape is dependent on 
factors such as age at time of contact, season, environment, race, and sequence of 
encounters. Especially viruses trigger cytotoxic-T-lymphocytes to differentiate and 
proliferate to specific subpopulations. For example, after primary cytomegalovirus 
(CMV) contact, a persistent increase of CMV-specific terminally differentiated 
Tc-lymphocytes (CD3+CD8+CD45RA+CD27-) is seen; CMV leaves a typical fingerprint in 
the Tc population.[28] The individual set-point is defined by the degree of immuno-
competence during the primary CMV-contact: immunocompromised people produce 
higher numbers of CMV-specific terminally differentiated Tc-lymphocytes in an 
attempt to keep CMV latent, but they are still more prone to CMV reactivation and 
severe infection-related morbidity.[29-31] The number of terminally differentiated Tc 
in combination with the clinical picture after primary CMV infection can therefore be 
Figure 1   Analysing lymphocytes in peripheral blood represents around 2% of  
the total lymphocyte population, as the majority of lymphocytes reside  
in primary (bone marrow, thymus) and secondary lymphoid organs  
(such as lymph node and spleen). 
Figure 1 is adapted from Werkboek Immunologie G.T. Rijkers et al.
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used as an indicator for an assessment of the immune status of the host during the 
encounter with CMV.
Vaccination types as models for T-cell (in)dependent antigen response
The adaptive immune system uses different pathways to respond to antigens: T-cell 
dependent (TD) and T-cell independent (TI), respectively. Different types of vaccination 
are used in this thesis as a model to study these different immune response pathways. 
All models have their limitations. A vaccine is not a surrogate for experiencing an 
infection for various reasons. The route is different: vaccinations are administrated 
intramuscularly in most cases, whereas pathogens invade across barriers (e.g. 
respiratory tract, skin) resulting in differences in antigen-presentation and immune 
response.
 Also, the composition is different: vaccinations are made of attenuated live 
viruses, inactivated or killed organisms, inactivated toxins or segments of the 
pathogens. They can contain extra elements, such as a carrier protein (conjugate) or 
adjuvants to boost the immune response and push the immune response in a certain 
direction: e.g. a TI or TD antigen response. In reality, most pathogens share properties 
of TD and TI antigens.[32-34] 
 Finally, comparison is difficult: different methods and vaccination schemes 
co-exist side-by-side, but universal antibody cut-off levels are being used despite of 
the differences. The majority of the documented protective antibody cut-off levels are 
based on studies performed in healthy males (e.g. soldiers), but they are applied to 
children and elderly as well. Post-vaccination protection for an individual should be 
based not only on the quantitative antibody level, but also on the antibody quality 
measured by avidity and opsonisation capacity and most importantly the lack of 
disease occurrence. However, for most vaccines, combined quantitative and qualitative 
studies and reference values specifically for children are lacking. 
T-cell dependent antigen response
The T-cell dependent antigen response is primarily determined by the combination 
of T-lymphocyte function, T-B interaction and B-lymphocyte function (Figure 2). 
An adequate T-cell dependent antigen response will ultimately lead to activated 
class-switched B-lymphocytes producing immunoglobulins with high affinity, and 
will also result in the formation of memory T- and B-lymphocytes. 
 Peptide antigen has to be processed and presented by an antigen-presenting cell 
(APC). Antigen-loaded APCs can then migrate to secondary lymphoid organs (e.g. 
lymph nodes, spleen) and present a specific antigen on their MHC-class II complex to 
the T-cell receptor (TCR) of helper-T lymphocytes (Th). If the MHC-class II-peptide 
complex is recognized by TCR of Th, an immunological synapse will be formed in the 













clusters of rings: in the centre, the B-cell or T-cell receptor which is bound to a 
MHC-antigen complex presented by APC, with surrounding clusters consisting of 
different adhesion molecules. For example in the peripheral supramolecular activation 
cluster (pSMAC), lymphocyte function-associated antigen 1 (LFA-1) on Th binds to 
intercellular adhesion molecule 1 (ICAM-1) on APC. The immunological synapse 
coordinates cell-signalling, activation and differentiation. The Th becomes activated 
and moves towards B-cell areas in secondary lymphoid organs.
 B-lymphocyte activation is initiated following recognition of a specific antigen by 
the B-cell receptor (BCR). Activated B-lymphocytes can produce IgM instantly. The 
activated B-lymphocytes move towards the activated Th-lymphocytes in the 
secondary lymphoid organs and can present processed peptide-antigen on their 
MHC-II molecules to TCR of the abovementioned activated Th-lymphocytes. 
 With help from Th, B-lymphocytes can undergo class-switch recombination and 
somatic hypermutation. Apart from finding the right Th-B match, co-stimulatory 
molecules creating an immunological synapse between B-Th are necessary as well. 
Figure 2   Stepwise approach of T-cell dependent antigen response.
1.  Peptide antigen uptake and processing by antigen-presenting cell (APC).
2.  Immunological synapse between APC-Th: antigen presentation on MHC-II by APC to TCR on 
helper-T-lymphocyte (Th). Antigen-recognition by TCR on Th. Cellular binding between Th 
and APC through costimulating peripheral supramolecular adhesion molecules (pSMAC) 
such as LFA-1 and ICAM-1, creating an immunological synapse. 
3.  Activation of Th and Th movement towards B-cell areas, generating cytokines activating 
both Th and APC. 
4.  Antigen-recognition of B-lymphocyte by BCR, antigen presentation by APC possible. Antigen- 
processing and presentation on MHC-II by B-cell. Movement of activated B-cell in lymph 
node towards Th. 
5.  Immunological synapse between B-Th: antigen-presentation on MHC-II of B-cell to TCR on 
Th. Antigen-recognition by TCR on Th. Cellular binding between Th and B-cell through 
costimulating peripheral supramolecular adhesion molecules (pSMAC) such as LFA-1 and ICAM-1, 
creating an immunological synapse. CD40-CD40L connection necessary for class switch 
recombination (CSR) of activated B-lymphocytes towards the production of IgG, IgA or IgE.
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For instance, B-lymphocytes can only class-switch from the production of IgM to the 
production of IgG, IgA and IgE after interaction between CD40 molecules on 
B-lymphocytes with CD40L molecules on activated Th. Through this class-switch 
recombination (CSR) process, B-lymphocytes can adapt their Ig effector functions 
while maintaining antigen specificity. 
 Repeated exposure to T-lymphocyte dependent antigens activates selected 
clones of memory B-lymphocytes to undergo somatic hypermutation (SHM), leading 
to increased antigen specificity with higher affinity immunoglobulins. These processes 
also result in the production of memory B-lymphocytes inducing long lasting 
protection and faster immune responses when antigen is repeatedly encountered.[33, 
34] Examples of TD antigens used in this thesis are tetanus toxoid and influenza A/
H1N1 vaccinations. 
T-cell independent antigen response
Bacteria can use camouflage techniques to prevent Th help, for instance by using a 
coat of polysaccharides. B-lymphocytes can mount an immune response against 
these polysaccharides without T-cell help, because these molecular structures are 
repetitive and therefore do not need peptides or antigen-presentation on MHC to 
activate the B-lymphocyte. This is called a T-cell independent (TI) type 2 immune 
response (Figure 3a). Polysaccharides can extensively crosslink B-cell antigen receptors 
and deliver a prolonged and persistent signal to the B-lymphocyte.[32] TI immune 
response is essential for rapid antibody production and early protection especially 
to blood-borne pathogens. However, without Th help, no B-lymphocyte class 
switch recombination or somatic hypermutation will take place and no memory 
B-lymphocytes will be produced. The TI immune response can be used to investigate 
the maturation and quality of B-lymphocytes. An example of a specific TI type 2 
antigen used in this thesis is 23-valent pneumococcal polysaccharide vaccine (PPV23).
 The immature adaptive immune system in infants under 2 years of age is unable 
to induce an adequate TI response in response to polysaccharides. To overcome this 
problem, new types of vaccines have been developed. By conjugating a peptide to the 
polysaccharide antigen, an adequate TD immune response can be induced, even in 
young children (Figure 3b). Examples of this type of immune response used in this 
thesis are the heptavalent pneumococcal conjugate vaccine (PCV7) and meningococcal 














This thesis gives more insight in the adaptive immune system of children with Down 
syndrome. In PART 1 both T- and B-lymphocytes subpopulations and immunoglobulin 
(IgG, IgA, IgM) levels in different age groups in DS children are analyzed. In Chapter 2, 
an overview of past literature on the DS adaptive immune system is given. Chapter 3 
investigates the current hypothesis of immunosenescence by comparing the literature 
on immunological alterations and clinical profiles in normal ageing, progeria 
syndromes and DS. In Chapters 4 and 5 both T- and B-lymphocyte subpopulations and 
immunoglobulin (IgG, IgA, IgM) levels in different age groups in DS children are 
analyzed and compared with healthy age-matched control children. Terminally 
differentiated cytotoxic-T-lymphocyte counts in relation to cytomegalovirus are 
compared with non-DS subjects with different immunocompetence status. The 
clinical picture of infections, autoimmune disease, allergy and malignancies is 
correlated with these quantitative results. In PART 2 the quality of B- and T-lymphocyte 
responses to different types of antigen is investigated through vaccination studies as 
a model for TD and TI immune responses. In Chapters 6-9 five different vaccinations 
Figure 3   Stepwise approach of T-cell independent antigen response (polysaccharide PS) 
and PS+conjugate.
A. PS: Extensive polysaccharide crosslinking on BCRs: B-cell activation signal 1. Extra activation 
through C3d recognition by CD21 on B-cell.  Extra stimulation through cytokines produced 
by macrophages/T-lymphocytes possible. TI antigen response: primarily IgM.
B. PS with conjugate: Th help possible through conjugate (peptide) uptake and processing by 
B-lymphocyte. Peptide antigen-presentation on MHC-II of B-cell to TCR on Th. Costimulating 
peripheral supramolecular adhesion molecules (pSMAC) creating immunological synapse, 
connection CD40-CD40L necessary for class switch recombination (CSR) of B-lymphocytes. 
Th activation: effector and memory cells, cytokine production. TD antigen response: 
primarily IgG. 
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are used. Tetanus toxoid (chapter 6), influenza A/H1N1 (chapter 7) are examples of 
protein antigens eliciting TD responses. Meningococcal C (MenC; chapter 8) and 
heptavalent pneumococcal conjugate (PCV7; chapter 9) vaccinations are examples of 
protein-conjugated polysaccharide antigens eliciting TD responses. 23-Valent 
pneumococcal polysaccharide vaccine (PPV23; chapter 9) is an example of a 
polysaccharide antigen eliciting a TI response. A comparison is made with data from 
the literature on ageing, on DiGeorge syndrome (DGS), thymectomy and HIV (all 
mainly T-lymphocyte deficiencies), and on common variable immunodeficiency 
disorders (CVID) and specific polysaccharide antibody deficiency (SPAD) (mainly 
B-lymphocyte immunodeficiencies). PART 3 contains the summary and discussion. 
AIM OF THE THESIS
In this thesis the following questions are addressed:
1. What alterations - both qualitative and quantitative - can be found in T- and 
B-lymphocytes in DS? 
2. Do these alterations fit the current hypothesis of early immunosenescence? 
3. Do children with DS have an intrinsic primary immunodeficiency (PID)?
4. Do the immunological alterations in combination with the clinical profile fit a 
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INTRINSIC DEFECT OF  
THE IMMUNE SYSTEM IN CHILDREN WITH 
DOWN SYNDROME; A REVIEW
MAA Kusters, RHJ Verstegen, EFA Gemen, E de Vries




Down syndrome (DS) is the most frequent cause of mental retardation in man. 
Immunological changes in DS have already been observed since the 1970s. The 
neurological system appears to be ageing precociously, with early occurrence of 
Alzheimer disease; until now, the observed immunological differences have been 
interpreted in the same context. Reviewing past and present results of immunological 
studies in DS children in relation to the clinical consequences they suffer, we conclude 








Down syndrome (DS), or trisomy 21, is the most frequent genetic cause of mental 
retardation in man; the incidence is approximately 1 in 750 live births [1]. Consequently, 
doctors frequently see patients with DS and encounter their complex medical 
problems. Individuals with DS are invariably cognitively impaired, although the 
severity is highly variable. Characteristic facial features and hypotonia are present in 
almost all patients; around 50% suffer from congenital cardiac anomalies. Congenital 
cataract, abnormalities of the gastro-intestinal tract and orthopaedic, eye and ear 
problems occur with increased frequency compared with non-DS individuals. Histo-
pathologic studies show a small and hypocellular brain and, by the fourth decade, 
characteristic features of Alzheimer disease [2, 3]. Autoimmune phenomena such as 
acquired hypothyroidism, celiac disease and diabetes mellitus occur in higher 
frequency compared with non-DS subjects. Leukaemia is estimated to be 15-20 times 
more frequent in DS [4-7]. Despite advances in treatment, infections - especially 
pneumonia - and leukaemia are still major causes of morbidity and mortality in DS 
[7-12]. The increased frequency of haematological malignancies, autoimmune diseases 
and infections in DS, and the observed high frequency of hepatitis B surface antigen 
(HBsAg) carriers, had already led in the 1907s to the hypothesis that DS is associated 
with abnormalities of the immune system [4, 13-16]. Indeed, many differences 
between the immune system of DS and non-DS individuals have been found 
throughout the years, and several hypotheses have been formulated which, if true, 
could have consequences for everyday clinical care in DS (findings relevant for everyday 
clinical care are summarized in Table 1).
Higher rates of infections, malignancies, and autoimmune phenomena are seen 
normally in elderly individuals [17-20], and DS was therefore hypothesized to be a form 
of abnormal precocious aging in various papers published in the late 1980s and early 
1990s (e.g. [21-22]), which are still being cited (e.g. [23]).
Natural killer cells and innate immunity
The supposedly higher percentages of natural killer (NK) cells found in DS seems to 
support this theory of precocious aging [21, 24], as high percentages of NK cells are 
seen normally with ageing. However, these studies were performed in small groups of 
DS individuals with single- and double-colour flowcytometric staining techniques 
that could not differentiate between NK cells (CD3-) and NK marker-bearing 
T-lymphocytes (CD3+). Our recent study on lymphocyte subpopulations in DS shows 
lower absolute numbers of CD3-CD16 and/or 56+ NK cells in all age groups [25]. 
Populations with different  NK-activity, capable of low, intermediate and high 
cytotoxicity against the NK-sensitive tumour cell line K562, respectively, were described 
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in the 1980s [26, 27]. Several authors describe a significant increase of cells possessing 
the low NK-activity phenotype in DS, associated with a significant decrease of cells 
with the intermediate and high NK-activity phenotype [21, 28]. With longevity, 
however, NK cells with well-preserved cytotoxic function increase [29].
Table 1   Overview of differences relevant to everyday clinical care found between 
the immune systems of DS and non-DS individuals since the 1970s.
Lymphocyte subpopulations Reference
CD3-CD16and/or56+ NK-cells Decreased (abs) [25]
CD19+ B-lymphocytes Decreased (abs; %) [24, 25]
CD3+ T-lymphocytes Decreased/normal (abs) [25]
CD3+CD4+ helper-T-lymphocytes Decreased (abs; %) [25]
CD3+CD8+ cytotoxic T-lymphocytes Decreased/normal (abs) [25]
CD4+CD45RA+ cells Decreased (%) [37, 38]
Th1/Th2 ratio Increased [69]
CD4/CD8 ratio Inverted ratio [22]
TCR-αβ+  T-lymphocytes Decreased (%) [37]
CD8+CD57+ cells Increased (%) [21]
Immunoglobulins
IgG Increased >6yr [15, 28, 30]
IgM Decreased >6yr [15, 28]
IgA Increased >6yr/normal [15, 30]
IgG1 Increased/normal [30, 70]
IgG2 Decreased/normal [30, 70]
IgG3 Increased/normal [30, 70]
IgG4 Decreased/normal [30, 70]
Response to vaccination
Pneumococcal polysaccharide vaccine Decreased/normal [28, 54]
Tetanus vaccine Decreased [74]
Pertussis vaccine (acellular) Decreased [58]
Hepatitis B vaccine Decreased/normal [52, 57, 60] 
Hepatitis A vaccine Normal [56]
Influenza vaccine Decreased [74]
Polio vaccine (oral) Decreased [59]
Abs, absolute counts; CD, cluster of differentiation; Ig, immunoglobulin; NK, natural killer; TCR, T cell receptor; 







The thymus is smaller in DS subjects, even in newborns, and has an abnormal structure 
[16, 26, 28, 30-32]. This suggests that T-lymphocytes are the core of the problem in DS; 
however, children with congenital heart disease who require cardiac surgery with 
(partial) thymectomy show rapid and permanent changes in T-lymphocyte numbers 
[33, 34] but, unlike in DS, their frequency of infections and autoimmune diseases is not 
increased [35]. The DS thymus shows a decreased proportion of phenotypically mature 
thymocytes expressing high levels of the αβ-form of the T-cell-receptor (TCR-αβ) and 
associated CD3-molecule [36], and overexpression of tumour necrosis factor (TNF)-α 
and interferon (IFN)-γ cytokines [27]. Overexpression of these cytokines suggests a 
dysregulation in cytokine production in DS and may provide an explanation for the 
abnormal thymic anatomy and thymocyte maturation [27]. An increased percentage 
of peripheral T-lymphocytes expressing the alternative γδ-form of the T-cell receptor 
(TCR-γδ) has been reported [26, 37], as well as a lower percentage of CD4+CD45RA+ 
naive cells – then considered to represent cells that have recently emigrated from the 
thymus - and a higher percentage of CD29+ memory cells [26, 38]. TCR excision circle 
(TREC) counts are used to estimate recent thymic emigrants (VDJ recombination 
events excise intervening stretches of DNA) [39]. A significantly lower number of 
TREC+ peripheral blood cells is found in DS children in comparison with healthy control 
children [23, 40]. These findings could be interpreted as early senescence of the 
immune system [26, 38], because naive helper- and cytotoxic T-lymphocytes [29, 41] as 
well as TREC+ peripheral blood cells [42] decrease with ageing, while central and 
effector memory helper-T-lymphocytes and effector memory and terminally 
differentiated cytotoxic T-lymphocytes increase [43]. We have recently demonstrated 
a T-lymphocytopenia in all age groups, however, not just in older DS children, that 
concerns CD4+ helper- as well as CD8+ cytotoxic T-lymphocytes with absence of the 
tremendous expansion that is seen normally in the first year of life, suggesting a 
deficient reaction to antigenic stimulation [25, 41, 44]. Absolute numbers of 
T-lymphocyte populations gradually approach those of normal children over time [25], 
but it is doubtful whether these cells have normal phenotype and function, having 
shown a lack of the antigen-driven expansion in earlier years. Functional abnormalities 
of T-lymphocytes that have been described support this: the in vitro proliferative 
response to phytohemagglutinin (PHA), is markedly below normal in DS infants and 
adults [15, 16, 45-47]. In addition, bacterial and viral antigen-induced in vitro interleukin-2 
(IL-2) production is reduced markedly, although PHA-stimulated IL-2 production is not 
impaired [13, 42, 43]. An interesting hypothesis is that overexpression of the cell 
adhesion molecules lymphocyte function-associated antigen-1 and DS cell adhesion 
molecule - located on chromosome 21 - causes higher affinity between cells leading to 
abnormal maturation and function [48, 49], but in most genetic studies in trisomy 21 
an overall 150% increase of gene expression is not seen; the genetic overexpression is 
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often specific for a particular organ [50]. Enhanced cell death by apoptosis could also 
play a role, as transgenic copper-zinc superoxide dismutase mice (in humans located 
on chromosome 21) show enhanced apoptosis [51].
B-lymphocytes and antibody production
A considerable hypergammaglobulinemia of immunoglobulin (Ig)G and IgA after the 
age of 5 years, with high levels of IgG1 and IgG3 and low levels of IgG2 and IgG4, is 
described in DS [15, 30, 52], with IgM levels decreasing in adolescence. IgD levels are 
high [53]. Antibody responses to rabbit erythrocytes and Escherichia coli antigens are 
low [28], as are the responses to vaccine antigens such as influenza A, oral polio, 
acellular pertussis, tetanus and polysaccharide pneumococcal vaccine [54-59]. The 
frequency of hepatitis B virus carriers is much higher among DS children compared 
with age-matched controls; however, normal responses to hepatitis A and B vaccinations 
are seen, although specific IgG-subclasses can vary [56, 60]. Autoantibodies against 
human thyroglobulin and gliadin are observed more often in DS children [15, 30, 61], as 
are high titres against casein and beta-lactoglobulin [15, 61].
 Somewhat paradoxically, we have recently found a profound B-lymphocytopenia in 
DS, with absence of the normal enormous expansion in the first year of life [25]. This has 
been described before [24, 28, 62, 63], but so far has attracted little attention. Recent 
observations even show a significant decrease of B lymphocytes (CD19+) in fetuses 
with DS [64]. These abnormalities can be either due to an intrinsic B-lymphocyte 
defect or to the consequence of deficient helper-T-lymphocyte function causing 
inadequate control of B-lymphocyte activation and proliferation. The combination of 
profound B-lymhocytopenia and hypergammaglobulinemia suggests the latter, 
with the possibility that antibody responses may be oligoclonal and/or inadequate 
in DS. However, we have found no mono- or oligoclonal M-proteins in 88 DS children 
(unpublished data). Also, in comparison, patients with DiGeorge syndrome (DGS; 
22q11-deletion) show a congenital thymic hypoplasia with a variable degree of 
T-lymphocyte deficiency in 80% of cases [65,66].  As in DS, TREC+ cell counts are 
decreased in the periphery, and T-lymphocytes gradually approach normal numbers 
over time [39] but – unlike in DS – B-lymphocytopenia is not seen in DGS [67, 68].
 Helper-T-lymphocyte type 1 cells (Th1) produce cytokines such as IFN-γ, IL-2, and 
TNF-α which stimulate cytotoxic T-lymphocyte responses and IgG1 and IgG3 
production, whereas helper-T-lymphocyte type 2 cells (Th2) produce cytokines such as 
IL-4, IL-5, IL-6, and IL-10 which stimulate antibody responses by B-lymphocytes and the 
formation of IgG2 and IgG4. In comparison to individuals with mental retardation (no 
DS) and healthy controls, DS adults have significantly higher percentages of IFN-γ- 
producing CD4+ and CD8+ cells and a higher Th1/Th2 ratio [69]. This fits the increased 
levels of IgG1 and IgG3 and decreased levels of IgG2 and IgG4 in DS, and supports 






Clinical presentation in relation to immunodeficiency
The clinical presentation of DS children, seen in relation to possible immunodeficiency 
[71], is dominated by recurrent ear-nose-throat (ENT) and airway infections in their 
early years, followed by an increasing frequency of autoimmune diseases and lympho-
proliferation thereafter. The recurrent ENT and airway infections could fit antibody 
deficiency, although the macroglossia, hypotonia, and altered anatomy of the upper 
airways will also play an important role in these infants. The tendency towards 
autoimmune diseases and lymphoproliferation, on the other hand, points primarily to 
immunodysregulation. Partial reduction in the number and function of T-lymphocytes 
can disturb the tolerogenic balance, generating a combination of immunodeficiency 
and immune dysregulation [72, 73]. DS children as a group could fit the picture of 
primary immunodeficiency, but with apparent individual differences. The relation 
between the abnormality of immunological values in individual DS children and the 
clinical complications has, so far, unfortunately not been studied extensively.
CONCLUSION
In summary, it is much more likely that the immune system in DS is intrinsically 
deficient from the very beginning, and not simply another victim of a generalized 
process of precocious ageing. It is not yet clear but at least possible that, next to the 
apparent thymus and T-lymphocyte abnormalities in DS, B-lymphocytes are also 
intrinsically different.
 Further studies are needed to resolve the underlying mechanisms of this immuno-
deficiency, and to assess the implications thereof for everyday clinical care. 
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DOWN SYNDROME: IS IT REALLY 
CHARACTERIZED BY PRECOCIOUS 
IMMUNOSENESCENCE?
MAA Kusters, RHJ Verstegen, E de Vries




The immune system declines with ageing, leading to an increased susceptibility to 
infections and higher incidence and progression of autoimmune phenomena and 
neoplasia. Down syndrome prematurely shows clinical manifestations that are 
normally seen with ageing. This review provides a concise overview of abnormalities 
in the adaptive immune system of Down syndrome in comparison to normal and 
precocious (Progeria syndromes) ageing. Clinical signs, immunological changes and 
genetics are reviewed. We challenge the hypothesis that the immunological 













In humans, as in all species, a progressive functional decline occurs with ageing in all 
organ systems due to loss and instability of genetic material. To protect the genome, 
chromosomes are capped by so-called telomeres which prevent degradation of genes 
near the ends of the chromosome. But with each cell division a small part of the 
telomere is lost. This proces is limited, but not prevented, by the enzyme telomerase 
which increases the length of the telomeres. Therefore, cumulative cell divisions 
ultimately result in genome instability and apoptosis of cells [1]. The immune system 
is essential for detection and elimination of pathogens and thereby for prevention of 
damage and degeneration of the organism. Lymphocytes continuously undergo 
proliferation [2]. So, especially lymphocytes are highly susceptible to telomeric 
shortening, leading to ageing of the adaptive immune system, which is often referred 
to as ‘immunosenescence’. As a result, the elderly are more susceptible to infections. 
Also, malignancies and autoimmune phenomena are more common with ageing due 
to failing immune surveillance secondary to immunosenescence [3, 4].
Down syndrome is the most frequent genetic cause of mental retardation in man; it is 
caused by an extra chromosome 21. People with Down syndrome (DS) prematurely 
show signs that are normally seen with ageing; for example, adults with DS show 
early signs of Alzheimer’s disease [5]. Also, clinical features reminiscent of immunose-
nescence are seen, with higher rates of infections, malignancies, and autoimmune 
phenomena. It is therefore not illogical to hypothesize that the immune system in DS 
shows accelerated ageing as well [6].
This review provides a concise overview of the abnormalities found in the DS immune 
system in comparison to normal immunosenescence and the immunological findings 
in the precocious aging or Progeria syndromes (PS) [7]. The scope of this article is not 
exhaustive with respect to this complex topic, but attempts to show that the immune 
alterations in DS should – in spite of previous publications on the subject – not be 
interpreted as precocious immunosenescence [8].
The adaptive immune system 
The immune system defends the human body against invading micro-organisms. 
It consists of two parts: the innate and the adaptive immune system. The innate 
immune system provides a primary immune response. Although a fast reaction takes 
place within minutes to hours, no memory is generated. The innate immune system 
therefore provides only short-term solutions. The adaptive immune system plays a 
pivotal role for long-term survival.[9] An essential difference between innate and 
adaptive immune cells is that the latter react specifically to a myriad of antigens while 
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providing long-term memory as well. Since immunoscenesence primarily affects the 
adaptive immune system, this system will be the focus of this review.
Key players in the adaptive immune response are B- and T-lymphocytes. B-lymphocytes 
are responsible for humoral immunity by producing specific antibodies. T-lymphocytes 
are accountable for cellular immune responses by helping other immunological cells 
through cytokine production and stimulation, and by direct cytotoxicity. Both T- and 
B-lymphocyte precursors are generated from hematopoietic stem cells in the bone 
marrow. While B-lymphocytes fully develop in the bone marrow, T-cell-precursors 
migrate to the thymus for further proliferation and development. In the secondary 
lymphoid organs (spleen, tonsils, lymph nodes) antigens are collected and presented. 
Also, T- and B-lymphocytes migrate there, and proliferate and differentiate into 
different effector and memory subsets after stimulation.
Within the thymus, T-cell-precursors can only survive if their T-cell receptors can 
interact with self major histocompatibility complexes (MHC) expressed on cell 
membranes, so-called positive selection. Too strong binding to self-antigens leads to 
cell death by negative selection, no binding at all results in cell death by neglect. 
Thymocytes binding to MHC-type II differentiate into helper-T-lymphocytes (Th), 
thymocytes binding to MHC-type I differentiate into cytotoxic-T-lymphocytes (Tc). 
As only antigen-presenting cells such as B-lymphocytes, dendritic cells and phagocytes 
express MHC-type II molecules, Th can only interact with these types of cells. Th are 
responsible for coordination and communication with both innate and adaptive 
immune cells; they serve as immunoregulators. Tc interact with MHC-type I expressing 
cells, which almost all human cells are, and can act directly as “killing machines” after 
activation and proliferation. Tc are especially suitable for strong cellular immune 
responses against tumour cells and intracellular pathogens such as viruses, whereas 
Th can help both humoral and cellular immune responses. The continuous generation 
of new Th and Tc from the thymus is crucial to maintain a functional immune system. 
Primary B-cell development takes place in the bone marrow. A unique B-cell antigen 
receptor is created on each B-lymphocyte membrane through gene rearrangements 
without previous antigen-exposure. B-lymphocytes do not need MHC for antigen 
recognition and can respond not only to peptides, but also to polysaccharides. Naive 
B-lymphocytes react to antigen exposure by producing immunoglobulins (Igs), 
primarily IgM. Extracellular pathogens such as bacteria are the main focus for these 
Igs. T-lymphocytes and T-lymphocyte-derived factors are necessary for further 
B-lymphocyte development. With the help of Th, B-lymphocytes can class-switch to 
the production of IgG, IgA and IgE, with altered effector function while maintaining 












selected clones of memory B-lymphocytes to undergo somatic hypermutation (SHM) 
leading to higher affinity Igs. 
The net result of all these processes is a broad diversity of B- and T-lymphocytes, 
which can survive for many years and provide resistance against the pathogens 
attacking the human body. 
Down syndrome compared to normal ageing
A comparison between the adaptive immune systems of Down syndrome, normal 
ageing and PS is summarized in Table 1. 
T-lymphocytes
The continuous release of new Th and Tc from the thymus is crucial for maintaining a 
functional immune system. Recent thymic emigrants all carry T-cell receptor 
rearrangement excision circles (TREC) as a by-product of DNA recombination 
processes. TRECs are not replicated and therefore diluted in the progeny that is formed 
after cell division. The TREC content can therefore be used to estimate the thymic 
output and also – indirectly – to estimate the thymic involution with ageing.
 With ageing the renewal capacity of stem cells declines, the hematopoietic tissue 
in the bone marrow decreases, and thymic involution with low peripheral blood TREC 
counts ensues [1]. T-lymphocytes can influence their own differentiation and 
proliferation process in the thymus and periphery by cross-talk and feedback- 
mechanisms. Decreased output of thymic emigrants can therefore normally be 
compensated in ageing individuals by an increase in effector and memory Th and Tc 
numbers. In this way, total T-lymphocyte counts remain relatively stable in ageing 
adults despite decreasing naive counts, as effector and memory subsets fill up the 
T-lymphocyte pool [3, 4]. However, these T-lymphocytes are continuously antigen- 
driven and eventually accumulate in “dead end” T-lymphocyte subsets such as 
terminally differentiated (TD) Tc. In other words, the T-lymphocyte pool becomes 
more experienced but less flexible with ageing, and the cells show a restricted 
repertoire and reduced proliferative response [3, 4].
 People with DS show T-lymphocyte abnormalities from an early age onwards. 
Newborns and fetuses with DS already show an altered thymic anatomy with impaired 
thymic output and lower TREC counts [10]. Some interesting candidate genes 
influencing thymocyte production by altered cross-talk and feedback-mechanisms can be 
found on chromosome 21. For example, increased expression of DS-cell-adhesion 
molecules on thymic epithelia and thymocytes can cause abnormal T-lymphocyte 
maturation and inefficient T-lymphocyte release to the peripheral blood [11]. Naive Tc 
and Th are decreased from birth [18]. Apart from decreased production, proliferation 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































first years of life. Memory Tc show a gradual increase over time, but in contrast to 
normal ageing memory Th do not. The expansion of TD Tc with normal ageing is not 
seen in DS either [12].
 The continuous DNA rearrangement processes make the lymphocyte pool 
extremely vulnerable to DNA errors. Lymphocytes are capable of upregulating 
telomerase and can thereby prolong their lifespan [1, 2]. The constant microbial 
pressure throughout life leads to an ongoing proliferative demand, which ultimately 
results in genome instability, senescence and apoptosis of cells. Enhanced cell death 
by apoptosis could play an extra role in DS besides decreased T-lymphocyte production 
and proliferation. Increased telomere shortening is found in DS T-lymphocytes, which 
could lead to higher apoptosis rates [13-16]. Recent studies however did not find 
increased apoptosis in peripheral T-lymphocytes, despite increased apoptosis markers 
on T-lymphocytes in earlier reports [10, 17, 18].
 Functional impairment in DS T-lymphocytes is supported by decreased proliferative 
and antigen T-cell responses [10]. Functional T-lymphocyte impairment could explain 
the increased incidence of haematological malignancies. 
B-lymphocytes
With ageing, fewer B-lymphocytes are produced in the bone marrow. Total peripheral 
B-lymphocyte numbers do not decline with age, but the composition of the peripheral 
B-lymphocyte compartment changes: antigen-experienced memory B-lymphocytes 
increase and naive B-lymphocytes decrease in number. Memory B-lymphocytes with 
a decreased susceptibility to apoptosis accumulate in elderly persons, leading to clonal 
expansions of certain B-lymphocyte specificities, which may limit the diversity of the 
repertoire [3, 4].
 Alterations of the B-lymphocyte compartment in DS are on the contrary present 
from birth onwards: newborns show decreased naive B-lymphocyte numbers, early 
expansion is absent, and memory B-lymphocytes do not increase with age. This 
results in extremely low total B-lymphocyte counts [19, 20].
 Although serum immunoglobulin levels remain stable during normal ageing, 
antibodies generated in old age are of lower affinity because of an age-associated 
decrease in somatic hypermutation due to decreasing help from Th, and restricted 
B-lymphocyte repertoire due to clonal expansions. 
 In DS, despite the low B-lymphocyte numbers, a profound hypergammaglobulin-
emia develops from around 3 years of age onwards, without evidence of mono- or 
oligoclonality [21]. This hypergammaglobulinemia with increased IgG, IgG1 and IgG3, 
but decreased IgM, IgG2 and IgG4 serum levels [21] is more suggestive of dysregulation 
in class-switching and somatic hypermutation of B-lymphocytes within the germinal 
centers than an impaired B-lymphocyte production in the bone marrow. An altered 
Ig-pattern can result from both an intrinsic defect in DS B-lymphocyte activation and 
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proliferation or B-T-miscommunication in the periphery. Decreased numbers of Th 
type 2 – essential for the humoral immune response – have  been reported in patients 
with DS [10] and could be associated with this altered Ig-pattern through impaired 
SHM and class-switching.
Immunizations
An indirect way to look at B-T-lymphocyte communication and the functional capacity 
of B- and T-lymphocytes is by studying vaccination responses. The specific antibody 
response to T-cell dependent protein antigens requires combined T-lymphocyte function, 
T-B interaction and B-lymphocyte function, whereas the response to T-cell independent 
polysaccharide antigens is largely determined by B-lymphocyte function alone. 
 The age-related decreased output and functional deficiency of the T- and 
B-lymphocyte pool hampers the adaptive immune response to both T-cell dependent 
and independent booster- and neo-vaccinations in the elderly [4]. Quantitative 
antibody responses are lower, decline faster and the affinity of the antibodies is 
diminished [4, 22-24].
 Impaired specific antibody responses to both T-cell-dependent (e.g. tetanus [25], 
influenza [26]) and T-cell-independent (e.g. pneumococcal polysaccharide [27]) 
vaccines [28] are repeatedly reported in DS as well, which suggests both altered T- and 
B-lymphocyte function and communication. 
Clinical relevance
The restricted B- and T-lymphocyte repertoire in the elderly, with antibodies of lower 
affinity, leads to immunodeficiency and immunodysregulation, resulting in a trias of 
higher infection and malignancy rates and more auto-immune phenomena such as 
rheumatoid arthritis (RA) [29]. This clinical trias is seen in DS as well. The increased 
susceptibility to respiratory tract infections in DS could – at least in part – be explained 
by a combination of anatomic and functional ear-nose-throat abnormalities, 
hypotonia, mental retardation and increased incidence of gastro-oesophageal reflux, 
but these cannot explain the increased auto-immune phenomena and hematological 
malignancies [30]. Although patients with DS have the same clinical trias of increased 
infections, malignancies and auto-immune diseases as the elderly, in practice the 
actual pathogens and disease-burden are to some extent different [31]. In DS a higher 
frequency of mainly hypothyroidism [33], celiac disease [34] and diabetes mellitus 
type 1 [35] is seen. Malignancies in DS consist mostly of haematological ones in 
contrast to elderly with an increase in non-haematological malignancies as well [36]. 
Progeria syndromes
Progeria syndromes (PS) are very rare diseases, leading to precocious and/or 












PS are only segmental in nature; they do not cause early or accelerated ageing in all 
human cell lines. Also, humans with PS can present symptoms that are not common 
during normal ageing [7].  PS can be further subdivided in different groups on the 
basis of the underlying genetic defect [7]. Hutchinson-Gilford progeria syndrome 
(HGPS) is the first described PS; LMNA gene mutation results in accumulation of lamin A 
protein in the cell nucleus. Werner syndrome – also called adult-onset progeria – is 
caused by a mutation in ATP dependent helicase leading to repair defects in DNA- 
double-strand breaks, but with slower onset than HGPS. Cockayne syndrome (CS) and 
xeroderma pigmentosum (XP) are examples of DNA-repair defect disorders causing 
progeria-like disease. Because of the segmental nature of most PS, it is not always 
clear whether and to what extent haematological cell lines are influenced [7]. The 
immune system in these progerias has only been studied in case reports and small 
cohort studies.  In a case report of a child with HGPS [37] increased B-lymphocyte 
numbers with severely decreased IgG and IgA serum levels were seen. In 12 adults with 
HGPS however normal levels of Igs and normal B- and T-lymphocyte counts were 
found (including Th and Tc) [38]. Five adults with Werner syndrome showed normal 
immunoglobulin levels, normal relative B- and normal to decreased relative 
T-lymphocyte counts [39]. Neoplasms and infections were found to be more frequent 
in Werner syndrome, which could be interpreted as clinically suggestive of immuno-
senescence. However, these neoplasms (eg sarcomas, melanomas) do not always 
overlap with commonly occurring neoplasms in ageing [40]. 
 XP patients have normal T-lymphocyte (including Tc and Th) counts, but decreased 
natural killer activity [41-43]. CS patients show normal T-lymphocyte counts; their 
NK-activity is normal [41]. XP patients have an increased risk of skin cancer, but 
apparently no increased risk of infections and auto-immune diseases. CS patients 
have no associated increased cancer risk, possibly due to normal NK cell and 
T-lymphocyte related immune surveillance [41].
More research is needed, but it seems that the picture in progeria and progeria-like 
syndromes is not comparable to normal ‘immunosenescence’; it is not the same in the 
different subtypes of PS and moreover is very different from the picture in DS.
 
CONCLUSION
At first sight, the DS profile seems to fit in with precocious immunosenescence, as 
thymic involution with low thymic output and T-lymphocyte dysregulation resulting 
in higher rates of infections, malignancies and auto-immune disease occur both in DS 
and normal ageing. Appearances however can be deceptive. 
 The decreased naive B- and T-lymphocyte production from birth onwards 
combined with the lack of compensatory memory cell expansion and proliferation do 
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not support precocious immunosenescence in DS; these findings fit intrinsic immuno-
deficiency better. The hypergammaglobulinemia in combination with decreased 
specific antibody responses support the theory that patients with DS harbor a 
combined T- and B-lymphocyte immunodeficiency with different mechanisms 
involved than in normal ageing. Progeria syndromes are not comparable to DS either. 
PS show segmental aspects of accelerated/precocious ageing at most reflected in 
minor lymphocyte changes. Also, the PS clinical profile differs from DS with respect to 
the occurrence of malignancies, infections and auto-immune diseases.
 Therefore, we challenge the hypothesis that the immunological abnormalities in 
Down syndrome should be interpreted as precocious immunosenesence. More 
genetic and immunological research is needed to study the true nature of the effect 
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BOTH NORMAL MEMORY COUNTS 
AND DECREASED NAIVE CELLS FAVOR 
INTRINSIC DEFECT OVER EARLY 
SENESCENCE OF DOWN SYNDROME 
T-LYMPHOCYTES
MAA Kusters, EFA Gemen, RHJ Verstegen, PC Wever, E de Vries




Because of their increased malignancies, autoimmune diseases, and infections, 
patients with Down syndrome (DS) show features of immunodeficiency. The DS 
thymus and T-lymphocyte subsets have indeed proven to be different, and this has 
been interpreted as precocious ageing. Our study on T-lymphocyte subpopulations in 
DS shows that the normal expansion of naive helper- (CD4+CD45RA+) and cytotoxic 
(CD8+CD45RA+CD27+) T-lymphocytes is lacking in the first years of life; which is more 
logically explained by an intrinsic T-lymphocyte defect. Furthermore, memory cell 
numbers are not different from age-matched controls (AMC), which do not support 
the hypothesis of precocious ageing. Although the absolute numbers of T-lymphocyte 
subpopulations approach AMC levels towards adulthood, the persistent clinical 
problems suggest that these cells may not function optimally. However, the clinical 
picture does not fit severe T-lymphocyte deficiency. The latter concept is also 
supported by our finding that cytomegalovirus (CMV)-seropositive DS children show 
similar numbers of terminally differentiated cytotoxic T-lymphocytes when compared 












Down syndrome (DS) is associated with a high frequency of haematological 
malignancies [1-4], autoimmune diseases like celiac disease and hypothyroidism [5-7], 
as well as recurrent, mainly respiratory, infections [2, 8]. This fits with immunodefi-
ciency. Indeed, the thymus in DS children is smaller and abnormal [9-13], and blood 
T-lymphocyte subpopulations differ from healthy controls [14-16]. This has been 
interpreted as precocious ageing of the immune system due to the lower relative 
number of CD4+CD45RA+ naive T-lymphocytes [17, 18] and lower T-cell-receptor 
excision circle counts [19, 20] in DS children. However, we recently showed [21] that the 
vast expansion of T-lymphocytes in the first years of life is abrogated, favoring an 
intrinsic defect. We studied T-lymphocyte subpopulations in DS children compared 
with age-matched controls (AMC) to analyze whether the results support this 
alternative theory.
 T-lymphocyte differentiation and expansion are influenced by encountered viral 
infections. Especially, the expansion of CD45RA+CD27- terminally differentiated 
cytotoxic T-lymphocytes (Tc), which is described as unique for cytomegalovirus (CMV) 
infection. The individual set-point is defined by the degree of immunocompetence 
during the primary CMV-contact: immunodeficient children show higher median 
absolute numbers of terminally differentiated Tc [22]. To further assess the degree of 
immuno(in)competence in DS, we related T-lymphocyte subpopulations to 
CMV-serostatus and compared the DS children with groups from the literature with 
different immune status during primary CMV-contact [22, 23].
METHODS
Study population
An extra 3 ml of EDTA blood and 7 ml of blood without additive was drawn from 95 
non-institutionalized DS children (49 males; mean age 7 years, range 1-20) visiting the 
Jeroen Bosch Hospital, ’s-Hertogenbosch, or the Rijnstate Hospital, Arnhem, The 
Netherlands, during routine follow-up of thyroid function after parental informed 
consent. All children were otherwise healthy at the time of sampling. Leftover EDTA 
blood from 33 healthy AMC children who underwent venipuncture for e.g. pre-operative 
screening for minor surgery, was used as control. The study was approved by the local 
Medical Ethics Committees of all participating hospitals.
 We divided the children into the same age groups that were used in a large Dutch 
reference study analyzing lymphocyte subpopulations [24]. Absolute and relative 
numbers of T-lymphocyte subpopulations were compared in DS and AMC children. 
Absolute numbers of terminally differentiated Tc of CMV-seropositive (CMV+) DS 
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children were compared with CMV-seronegative (CMV-) DS children and with the 
results from the evaluation and discussion from recent literature [22, 23] including 
children with human immunodeficiency (HIV) infection, children using immunosup-
pressive therapy and children who were otherwise healthy at the time of primary 
CMV-contact. 
Immunophenotyping
Three-color flow cytometric immunophenotyping was performed to determine 
T-lymphocyte subpopulations in both DS and AMC using the lysed whole-blood 
method. FITC-, phycoerythrin (PE)- and PE-cyanin 5 (PE-Cy5)-conjugated MAb were 
used with the following antigen specificity: CD3 (PE-Cy5; Immunotech, Marseille, 
France), CD3/CD4 (FITC/PE; IQProducts, Groningen, The Netherlands), CD8 (PE-Cy5; 
Immunotech), CD14 (PE; Beckton Dickinson (BD), San Jose, CA, USA), CD15 (FITC; IQ 
Products), CD16/CD56 (FITC; BD), CD19 (PE-Cy5; Immunotech), CD27 (FITC; BD), CD45 
(PE-Cy5; Immunotech), CD45RA (PE; Coulter Immunology, Hialeah, USA), CD45RO 
(FITC; Serotec DPC, Apeldoorn, The Netherlands), TCR-αβ (PE-Cy5;BD) and TCR-γδ (PE; 
BD).
 Aliquots were incubated for 15 minutes at room temperature with different 
combinations of optimally titrated conjugated MAb to determine the following 
lymphocyte subpopulations: T-lymphocytes (CD3+), B-lymphocytes (CD19+), natural 
killer (NK) cells (CD16+and/orCD56+CD3-), helper-T-lymphocytes (Th) (CD3+CD4+), Tc 
(CD3+CD8+), naive Th (CD3+CD4+CD45RA+), memory Th (CD3+CD4+CD45RO+), naive Tc 
(CD8+CD45RA+CD27+), central memory Tc (CD8+CD45RA-CD27+), effector memory Tc 
(CD8+CD45RA-CD27-), terminally differentiated Tc (CD8+CD45RA+ CD27-), CD3+TCR-αβ+ 
and CD3+TCR-γδ+ T-lymphocytes. Erythrocytes were lysed using FACSLysing solution 
(BD) according to the manufacturer’s protocol. The remaining cells were washed twice 
with PBS with BSA and analyzed by flow cytometry after calibration with the SPHERO 
CaliFlow kit (Spherotech, Libertyville, IL, USA) as recommended by the European 
Working Group on Clinical Cell Analysis [25]. A FACScan or FACSCalibur flow cytometer 
(BD) was used. Absolute leukocyte counts were determined with a Sysmex SE-9500 
hematology analyzer (Sysmex, Kobe, Japan).  The lymphocyte gate was checked with 
a CD15/CD14/CD45 triple labeling and considered correct if <5% contamination was 
present. B-lymphocytes and NK cells were used to check whether the T+B+NK equaled 
100 ± 5%. Absolute numbers of lymphocyte subpopulations were calculated by 
multiplying the absolute leukocyte count (x109/l) by the relative total lymphocyte size 
(%) and relative size of the lymphocyte subpopulation (%).
CMV serology and PCR
Anti-CMV IgM and IgG were measured in duplo by enzyme-linked fluorescence 










children, serum was not available. IgG avidity tests (VIDAS, Biomerieux) were 
performed to differentiate between recent (<3 months) and late CMV contact. 
Real-time PCR for CMV-DNA [22] was performed in CMV-IgG+ children to differentiate 
between active and latent infection. 
Review of medical files
The medical files of 91/95 DS children were reviewed retrospectively; four files were 
unavailable. The 91 children were divided into four groups: 1) no increased infection 
rate, 2) increased infection rate (age at inclusion <8 years), 3) increased infection rate 
(age at inclusion >8 years), and 4) increased infection rate until, but not after the age 
of 8 years. In addition, the presence of celiac disease or autoimmune hypothyroidism 
was noted.
Statistical analysis
To compare the T-lymphocyte subpopulations between DS and AMC the Mann 
Whitney U-test was used (p<0.05). An analysis of variance (completely randomized 
two-factorial design; p<0.05) was applied to the data to test the overall effects of age 
(2-16 years) and group (DS and AMC). Age groups with low numbers of AMC children 
were excluded (<2 yr; >16 yr) from this analysis. Levene’s test for equality of error 
variances was used on all subpopulations (p<0.05). Tc subpopulations of CMV-sero-
negative (CMV-) and CMV+ DS children were analyzed after log transformation by 
t test (p<0.05). All analyses were performed with SPSS 16.0 for Windows. 
RESULTS
The absolute and relative numbers of the analyzed CD3+ T-lymphocyte subpopulations, 
and the results of the statistical analyses are listed in table 1 (the values for CD3+ 
T-lymphocytes, CD3+CD4+ Th, and CD3+CD8+ Tc were reported before [21]). None of the 
interaction effects were significant. This means that the effects of age on the various 
T-lymphocyte subpopulations do not differ between DS children and AMC children; 
although T-lymphocytes and Th lack the expansion normally seen in the first years of life 
[24], the overall pattern seen in time is the same in DS and AMC. Clinically relevant data 
is presented in Table 2. We did not find a relation between any of the determined 
T-lymphocyte subpopulations and the incidence of infections or autoimmune diseases 
in these DS children.
Naive and memory CD3+CD4+ Th
The absolute numbers of CD45RA+ naive Th are reduced in DS children. Naive Th lack 
the expansion seen in AMC children during the first years of life, but the overall pattern 
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Table 1   Absolute and relative numbers of T-lymphocyte subpopulations.
9–15 months 15–24 months 2–5 years 5–10 years 10 –16 years >16 years DS vs AMC
(2-16 years) *
Age effect 






























































































































































































































Table 1   Absolute and relative numbers of T-lymphocyte subpopulations.
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Table 1   Continued.
9–15 months 15–24 months 2–5 years 5–10 years 10 –16 years >16 years DS vs AMC
(2-16 years) *
Age effect 
(DS+AMC;     
2-16 years) **



























































































































































































































Table 1   Continued.
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2-16 years) **



















































































































































































































seen in time is the same in both DS children and AMC children. Despite increased 
relative numbers of CD45RO+ memory Th, absolute numbers do not differ from AMC 
children due to the lower absolute counts of total Th in DS children. The memory Th 
subset does not show an age-related change in size in either DS or AMC children 
(Figure 1).
Naive, central memory, effector memory and terminally differentiated CD8+ Tc
Like naive Th, the absolute numbers of CD45RA+CD27+ naive Tc are decreased in DS, 
and lack the normal expansion seen in AMC during the first years of life, although the 
overall pattern seen in time is the same in DS and AMC. The absolute numbers of both 
CD45RA-CD27+ central memory and CD45RA-CD27- effector memory Tc are higher in 
DS than in AMC, but values differ widely (Levene’s test: p=0.009 and p=0.003, 
respectively). The absolute numbers of CD45RA+CD27- terminally differentiated Tc are 
low in all age groups in both DS as well as AMC children. Neither in memory Th, the 
memory Tc subsets show an age-related change in size in DS or AMC (Figure 2).
TCR-αβ+ and TCR-γδ+ CD3+T-lymphocytes
The absolute number of TCR-γδ+ T-lymphocytes in DS children is lower, but values 
widely differ in AMC children (Levene’s test: p=0.000). As was expected, the absolute 
numbers of TCR-αβ+ T-lymphocytes follow the pattern of total T-lymphocytes. 
Table 1   Continued.
9–15 months 15–24 months 2–5 years 5–10 years 10 –16 years >16 years DS vs AMC
(2-16 years) *
Age effect 












































Grey shaded areas: absolute numbers of T-lymphocyte subpopulations (109 cells/l), blank background: 
relative numbers (%); AMC = age-matched control children; DS = Down syndrome children; NS = not 
significant; centr mem = central memory; eff mem = effector memory; term diff = terminally differentiated 
* Analysis of variance, effect of group (children aged 2-16 years).** Analysis of variance, DS and AMC children 
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9–15 months 15–24 months 2–5 years 5–10 years 10 –16 years >16 years DS vs AMC
(2-16 years) *
Age effect 












































Grey shaded areas: absolute numbers of T-lymphocyte subpopulations (109 cells/l), blank background: 
relative numbers (%); AMC = age-matched control children; DS = Down syndrome children; NS = not 
significant; centr mem = central memory; eff mem = effector memory; term diff = terminally differentiated 
* Analysis of variance, effect of group (children aged 2-16 years).** Analysis of variance, DS and AMC children 
together (2 to 16 years), effect of age. 
Figure 1   Median absolute numbers (x 109/l) of helper-T-lymphocytes per age group.
A. Naive helper-T-lymphocytes (CD3+CD4+CD45RA+)
B. Memory helper-T-lymphocytes (CD3+CD4+CD45RO+).  
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CMV status and terminally differentiated CD8+ Tc
Twenty of the 90 tested DS children are CMV+, they all have a latent infection (IgG+IgM-; 
PCR- Avidityhi). The median absolute number of CD45RA+CD27-  terminally differentiated 
Tc in CMV+ DS children is 0.079 x 109 cells/l (range 0.007-0.36), and 0.017 x 109 cells/l 
(range 0.0004-0.22) in CMV- DS children (p<0.001). In CMV+ healthy children a median 
absolute number of CD45RA+CD27- terminally differentiated Tc of 0.067 x 109 cells/l is 
described [22]. Higher absolute numbers are described in children with primary CMV 
infection during immunosuppressive therapy (median 0.413 x 109 cells/l) and in CMV+ 
HIV-1 infected children (median 0.369 x 109 cells/l) (22, 23] (Figure 3).
Figure 2   Median absolute numbers (x 109/l) of cytotoxic T-lymphocyte subpopulations 
per age group.
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DS children lack the expansion of both naive Tc and naive Th normally seen in the first 
years of life; memory Tc and memory Th are not influenced by age in either DS or AMC 
children. With advancing age, numbers of memory Th, terminally differentiated Tc 
and TCR-γδ+ T-lymphocytes normally increase [17]. Despite earlier statements in the 
literature suggesting precocious ageing of T-lymphocytes in DS, no early shift towards 
these T-lymphocyte subsets occurred in our DS cohort. A more likely explanation of 
the observed T-lymphocyte subset alterations in DS children would therefore be that 
the decreased numbers of Tc but particularly of Th are the result of (partial) failure of 
T-lymphocyte generation, an intrinsic T-lymphocyte defect, increased apoptosis or a 
combination of these.  
 It is interesting to speculate about this finding. Apoptosis data in DS is scarce, but 
Elsayed [26] recently described increased early apoptosis markers in DS T-lymphocytes. 
Thymic alterations in DS are well-known [9, 10, 12, 13], and are already described in DS 
fetuses [27], suggesting T-lymphocyte generation is impaired by a defect in the DS 
thymus. This situation resembles children with DiGeorge syndrome who have a 
smaller or absent thymus; they demonstrate decreased (total) Th and Tc subsets as 
well [28, 29]. In DiGeorge syndrome, however, most cases appear to gradually reach 
T-lymphocyte levels of healthy adults over time. In comparison, naive Tc in our DS 
children reach normal levels during adolescence, but naive Th remain decreased. It is 
Figure 3   Median absolute numbers (x 109/l) of terminally differentiated cytotoxic 
T-lymphocytes per group.  
CMV: cytomegalovirus; DS: Down syndrome; HC: healthy children; HIV: human immunodeficiency virus 












still uncertain whether these cells function normally, having shown such a profound 
lack of the antigen-driven expansion in earlier years. In vitro tests of T-lymphocyte 
function support this hypothesis of impaired functioning [30].
 Clinically speaking, DS children do not show signs of a profound T-lymphocyte 
deficiency. This corresponds with our finding that CMV+ DS children show absolute 
numbers of terminally differentiated Tc comparable to healthy children, not to immuno-
compromised, e.g. HIV+, children. 
 In conclusion, the observed T-lymphocyte alterations in DS are more likely caused 
by an intrinsic defect than by early senescence of the immune system. In the future, 
functional studies of T-lymphocytes may help to differentiate between a defect 
primarily originating in the thymus (as in DiGeorge syndrome), a defect in the 
T-lymphocytes themselves, increased apoptosis, or a combination of these options. 
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DOWN SYNDROME B-LYMPHOCYTE 
SUBPOPULATIONS, INTRINSIC DEFECT OR 
DECREASED T-LYMPHOCYTE HELP?
RHJ Verstegen, MAA Kusters, EFA Gemen, E de Vries




Down Syndrome (DS) is known for increased incidence of respiratory infections 
and autoimmune diseases, indicating impaired immunity. Until now, attention has 
mainly been focused on T-lymphocytes. Therefore, we determined B-lymphocyte 
subpopulations in 95 DS children compared to 33 healthy age-matched control (AMC) 
children. DS serum immunoglobulin levels were compared with 962 non-DS children 
with recurrent infections. The results were combined with clinical data. Transitional 
and naive B-lymphocytes are profoundly decreased in children with DS. This could be 
caused by an intrinsic B-lymphocyte defect resulting in (partial) failure of B-lymphocyte 
generation, decreased antigen-induced proliferation and/or increased apoptosis, or by 
decreased proliferation due to deficient T-lymphocyte help, or a combination of these. 
The decreased CD27+, CD21high and CD23+ cells are reminiscent of common variable 
 immunodeficiency and suggestive of disturbed peripheral B-lymphocyte maturation. 
Immunoglobulin levels in DS are abnormal – as has been described before – and 
different from non-DS children with recurrent infections. We conclude that the 
humoral immune system is abnormal in DS, but could not find a relation between 
B-lymphocyte subset counts, immunoglobulin levels and clinical features of the DS 
children in our cohort, nor could we answer the question whether DS B-lymphocytes 












Down syndrome (DS) is associated with recurrent – mainly respiratory – infections [1, 2], 
decreased responses to vaccination [3-8], a higher frequency of hepatitis B surface 
antigen carriers [3] and autoimmune diseases like celiac disease and hypothyroidism 
[9-11]. These features are suggestive of immunodeficiency. Until now, attention 
has mainly been focused on the thymic alterations and decreased absolute numbers 
of T-lymphocytes in peripheral blood [12, 13]. We recently showed that a striking 
B-lymphocytopenia is present from the very beginning in patients with DS [14]. This 
B-lymphocytopenia could be due to an intrinsic B-lymphocyte defect, a deficient 
T-lymphocyte help, or a combination of these. An intrinsic B-lymphocyte defect could 
be due to (partial) failure of B-lymphocyte generation, decreased antigen-induced 
proliferation, and/or increased apoptosis. Deficient T-lymphocyte-help could lead to 
disturbed B-lymphocyte activation and proliferation. Despite the B-lymphocytopenia, 
a considerable hypergammaglobulinemia of IgA and IgG after the age of five years, 
with high levels of IgG1 and IgG3 and low levels of IgG2 and IgG4, is described [3, 15, 16].
 This combination of profound B-lymhocytopenia and hypergammaglobulinemia 
favors a disturbance in T-lymphocyte help, with the possibility that immunoglobulins 
are oligoclonal in DS, and specific T-cell-dependent antibody responses inadequate. 
The latter has indeed been described [3, 15]. However, the T-cell-independent antibody 
response to pneumococcal polysaccharide antigen is also decreased in DS [4], 
suggesting an intrinsic B-lymphocyte defect is also present. We studied B-lymphocyte 
subpopulations in relation to relevant clinical features in 95 DS children, to further 
unravel this question.  
METHODS
Study population
From 95 non-institutionalized children with DS (49 boys; Figure 1), either visiting 
the Jeroen Bosch Hospital, ’s-Hertogenbosch, or the Rijnstate Hospital, Arnhem, The 
Netherlands, an extra 3ml of EDTA and 7ml of blood without additive was drawn 
during routine follow-up of thyroid function after parental informed consent. All 
children were otherwise healthy at the time of sampling. Left-over EDTA blood from 33 
healthy age-matched control (AMC) children who underwent venipuncture, e.g. 
pre-operative screening for minor surgery, was used as control.
 We retrospectively collected the titers of serum IgG, IgA and IgM that were 
determined for diagnostic purposes in 962 non-DS patients suffering from recurrent 
infections (younger than 21 years) between January 2006 and July 2008 in the 
Jeroen Bosch Hospital, ‘s-Hertogenbosch, and the Bernhoven Hospital, Oss/Veghel, 
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The Netherlands. In 285 of the 962 patients IgG-subclasses were also determined.
The study was approved by the local Medical Ethics Committees of both hospitals.
Immunophenotyping
Three-color flowcytometric immunophenotyping was performed to determine 
B-lymphocyte subpopulations in both DS and AMC children using the lysed whole- 
blood method. FITC, phycoerythrin (PE), and PE-cyanin 5 (PE-Cy5) conjugated anti - 
bodies were used with the following antigen specificity: CD3 (PE-Cy5; Immunotech, 
Marseille, France), CD5 (FITC; Becton Dickinson (BD), San Jose, CA, USA), CD10 (FITC; 
BD), CD16/CD56 (FITC; BD), CD14 (PE; BD), CD15 (FITC; IQProducts, Groningen, The 
Netherlands), CD19 (PE-Cy5; Immunotech), CD20 (PE; BD), CD21 (PE; BD), CD23 (PE; 
BD), CD27 (FITC; BD), CD38 (PE; BD), CD45 (PE-Cy5; Immunotech), κ (PE; Dako, 
Carpinteria, CA, USA), and λ (PE; Dako). In all children T-lymphocytes (CD3+), 
B-lymphocytes (CD19+), natural killer (NK) cells (CD16+and/orCD56+CD3-) and CD21 
Figure 1   Patient flow diagram.
Flow diagram showing group size of patients with Down syndrome in relation to assessed 
variables.
Standard flowcytometric protocol (n=95)
Increased infection rate, celiac disease
and/or hypothyroidism? (n=91)
IgG, IgG subclasses, IgA, IgM and
M-proteins (n=88)
Extended flowcytometric protocol (n=55)



















and CD5 expression on CD19+ B-lymphocytes were determined. An extended protocol 
was used in the last included 55 children. In this group CD10, κ and λ expression, CD27 
and CD20 expression, CD27 and CD38 expression, and CD27 and CD23 expression on 
CD19+ B-lymphocytes were also analyzed.
Aliquots were incubated for 15 minutes at room temperature in the dark with different 
combinations of optimally titrated antibodies. Only for the samples that were 
incubated with anti-κ or anti-λ antibodies, the aliquots were washed three times with 
0.5% BSA/PBS before incubation. Erythrocytes were lysed using FACSLysing solution 
(BD) according to the manufacturer’s protocol. The remaining cells were washed twice 
with BSA/PBS and analyzed by flow cytometry after calibration with the SPHERO 
CaliFlow kit (Spherotech, Libertyville, IL, USA) as recommended by the European 
Society for Clinical Cell Analysis [17]. A FACScan or FACSCalibur flow cytometer (BD) 
was used in combination with CellQuest or CellQuest Pro software (BD). The lympho-
cyte-gate was checked with a CD15/CD14/CD45 triple labeling and considered correct 
if <5% contamination was present. T-lymphocytes and NK cells were used to check 
whether the ‘lymphosum’ (B+T+NK) equaled 100 ± 5%. Absolute leukocyte counts 
were determined with a Sysmex SE-9500 hematology analyzer (Sysmex, Kobe, Japan). 
Absolute numbers of B-lymphocyte subpopulations were calculated by multiplying 
the absolute leukocyte count (x109/l) by the relative total lymphocyte size (%) and 
relative size of the lymphocyte subpopulation (%).
Immunoglobulins
For 88 of the 95 children with DS, serum IgG, IgG1, IgG2, IgG3, IgG4, IgA, and IgM were 
studied; in seven children, serum was not available. IgG, IgA and IgM were determined 
by kinetic nephelometry (Beckman Coulter Array 360, Beckman Coulter, Fullerton, CA, 
USA); IgG-subclasses were assessed by kinetic nephelometry using a human 
IgG-subclass nephelometry kit (Sanquin Reagents, Amsterdam, The Netherlands).
 Qualitative M-proteins were assessed by serum electrophoresis on alkaline 
buffered (pH 9.2) agarose gels by a Hydrasys system (Sebia, GA, USA). In cases of 
uncertainty, additional serum electrophoresis using immunofixation with monovalent 
antiserum was performed.
 IgE was measured in 44 of the 55 children included in the extended protocol using 
a sandwich chemiluminescent immunoassay (Immulite 2500, DPC/Siemens, IL, USA); 
the volume of serum available was insufficient in 11 children. Specific IgE testing 
(Immulite 2500) of food and inhaled allergens was performed in 28 and 25 children, 
respectively. When insufficient serum was available, we tested for food allergens only 
for children aged <2 years and inhaled allergens only for children aged >2 years. The Fp5 
food allergen panel (DPC/Siemens) contained egg white, cow’s milk, codfish, soya, 
peanut and wheat allergen. The AlaTOP inhaled allergen panel (DPC/Siemens), 
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contained house mite (Dermatophagoides pteronyssimus), cat dander epithelium, dog 
dander, Bermuda grass, timothy grass, Penicillium notatum, Alternaria tenuis, birch, 
Japanese cedar, common ragweed (Ambrosia artemisiifolia), and English plantain and 
Parietaria officinalis allergen. To interpret the IgE results, we used our laboratory 
cut-off values of <50 U/ml for children aged <10 years, and <90 U/ml for children aged 
>10 years and adults.
Review of medical files
The medical files of 91 of the 95 children with DS were reviewed retrospectively; four files 
were unavailable. The 91 children were divided into four groups: 1) no increased infection 
rate, 2) increased infection rate (age at inclusion <8 years), 3) increased infection rate (age at 
inclusion >8 years), and 4) increased infection rate until, but not after, the age of 8 years. 
The presence of celiac disease or autoimmune hypothyroidism was noted. In addition, the 
55 patients of the extended protocol were also divided into positive or negative for 
symptoms of asthma and/or allergic disease (recurrent cough, persistent wheeze, admission 
on a pediatric ward for asthma exacerbation, clinical response to bronchodilators and/or 
inhalation corticosteroids, clinical signs of allergic disease). 
Statistical analysis
An analysis of variance (completely randomized two-factorial design; p<0.05) was 
applied to the data. For this analysis, we excluded those age groups for which the 
number of AMC data was too low. The two fixed factors in the analysis of variance 
were age (three age groups: 2-5 years, 5-10 years, and 10-16 years) and the difference 
between DS and AMC children. Levene’s test for equality of error variances was used, 
and the results are mentioned in the text only when p<0.05. The one sample t test 
(p<0.05) was used to compare the Ig values of DS children and non-DS children 
suffering from recurrent infections with the mean of age-matched reference values 
and each other [18, 19]. All analyses were performed with SPSS 16.0 for Windows.
RESULTS
B-lymphocyte subpopulations
The absolute and relative numbers of CD19+ B-lymphocyte subpopulations with 
results of statistical analyses can be found in Table 1, clinically relevant data are 
presented in Table 2. We did not find a relation between any of the determined 
B-lymphocyte subpopulations and the incidence of infections or of allergic complaints 
and/or asthma in these children with DS. The values for CD19+ B-lymphocytes were 
reported before [14]: the CD19+ B-lymphocyte count is significantly decreased in all 










healthy children in the first years of life, is lacking ([20]). The effect of age on the CD19+ 
B-lymphocyte count is significantly different between DS and AMC children 
(interaction for absolute values; Table 1), so this finding is highly significant. The κ/λ 
ratio is slightly increased in older DS children. CD5+ and CD5- B-lymphocytes follow the 
pattern of total CD19+ B-lymphocytes in children with DS. There is no evident increase 
of “immature” B-lymphocytes in DS: CD10+ and CD20- B-lymphocytes do not clearly 
differ between DS and AMC children.
 CD27-CD38dim naive B-lymphocytes and CD27-CD38+ transitional B-lymphocytes 
follow the pattern of total CD19+ B-lymphocytes in DS as well. Unfortunately, we 
cannot differentiate between CD27+CD38dimIgD+ marginal zone and CD27+CD38dimIgD- 
memory B-lymphocytes because the expression of IgD was not determined. Absolute 
and relative numbers of total CD27+ B-lymphocytes are decreased in DS compared 
with AMC children; the absolute numbers show a slight increase during the CD19+ 
B-lymphocyte expansion in the first years of life, which is less prominent in DS than in 
AMC children. The CD27+CD38++ plasma cell population is small in peripheral blood, 
but – unexpectedly – not different between DS and AMC children. The relative and 
absolute numbers of B-lymphocytes with high expression of CD21 (CD21high) are 
significantly decreased in DS children; the absolute numbers decline with age, but 
more so in AMC than in DS children due to a higher initial peak in the former. The same 
holds true for CD23. The relative expression of CD23 within the CD19+ B-lymphocyte 
population shows a far wider range in DS than in AMC children.
 
Immunoglobulins
The serum levels of IgG, IgG1, IgG2, IgG3, IgG4, IgA, and IgM found in the children with 
DS and in non-DS children with increased infection rates (see Methods section) in 
comparison with age-matched reference values are shown in Figure 2 [18,19]. In the DS 
group, mean IgG and IgG1 are already higher than the age-matched reference values 
from the ages of 2 and 3 years onwards, respectively (one-sample t-test; p<0.05). 
Mean IgA and IgG3 are normally distributed, but mean IgM and IgG2 are lower in 
children with DS in all age groups. IgG4 values are consistently very low in DS children. 
Mean Ig serum levels in the non-DS children with increased infection rates are similar 
to the children with DS for IgA and IgG2, but mean IgG is higher in  children with DS in 
some of the older age groups, and mean IgG1 and IgG3 are higher in children with DS 
from the ages of 3 and 2 years onwards, respectively. Mean IgM and IgG4 are lower in 
children with DS than in the non-DS children with increased infection rates in the 
older age groups. We did not find any mono- or oligoclonal M-proteins in the 88 DS 
children tested. IgE is increased in six of the 44 DS children tested; five showed high 
relative percentages of CD23+ B-lymphocytes which are within the range of the AMC 
group (one with asthma; data not shown). Specific IgE testing of food and inhaled 
allergens is negative in all children tested.
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Table 1   Absolute and relative numbers of B-lymphocyte subpopulations in  
Down syndrome children compared to age matched controls.


























































































































































































































































Table 1   Absolute and relative numbers of B-lymphocyte subpopulations in  
Down syndrome children compared to age matched controls.


















































































































































































































































Table 1   Continued.




























































































































































































































































































































































Table 1   Continued.




















































































































































































































































































































































Table 1   Continued.






















































































































































































































































































































































Table 1   Continued.














































































































































































































































































































































Table 1   Continued.








































Grey shaded areas: absolute numbers of B-lymphocyte subpopulations (109 cells/l), blank background: 
relative numbers (%); AMC = age-matched control children; DS = Down syndrome children; NS = not 
significant; * Analysis of variance, 2 to 16 years, DS versus AMC children. ** Analysis of variance, DS and AMC 
children together (2 to 16 years), effect of age. † Analysis of variance, interaction effect between DS and 
AMC children aged 2-16 years.
Figure 2   Immunoglobulin values in Down syndrome compared with reference values 
and children suffering from recurrent infections.
Values of a) IgG, b) IgA, c) IgM, d) IgG1, e) IgG2, f) IgG3, and g) IgG4 obtained in 88 children with DS 
are shown as black dots. x axis age in months; y axis immunoglobulin levels (g/L). The gray areas 
represent the values between the p2.5 and p97.5 of the determined immunoglobulin levels per 
age group in patients suffering from recurrent infections. Age-matched reference values (p2.5 
and p97.5) are shown as a black line.
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Table 1   Continued.








































Grey shaded areas: absolute numbers of B-lymphocyte subpopulations (109 cells/l), blank background: 
relative numbers (%); AMC = age-matched control children; DS = Down syndrome children; NS = not 
significant; * Analysis of variance, 2 to 16 years, DS versus AMC children. ** Analysis of variance, DS and AMC 
children together (2 to 16 years), effect of age. † Analysis of variance, interaction effect between DS and 












































































































































































































































































































































































































































































































































The profound B-lymphocytopenia in DS children, with decreased transitional and 
naive B-lymphocytes compared with AMC children, is the most striking result of our 
study. There are no indications for release of unusual numbers of “immature” 
B-lymphocytes from the bone marrow (CD10+, CD20-), the cells show the normal 
phenotype of the transitional and naive stages of peripheral B-lymphocyte 
development [22]. As stated before, this could be caused by decreased B-lymphocyte 
proliferation due to a disturbance in T-lymphocyte help, an intrinsic B-lymphocyte 
defect, or a combination of these.
 Interestingly, the distribution of B-lymphocyte subpopulations is reminiscent of 
the situation found in patients with common variable immunodeficiency (CVID) 
[23-25]: CD27+ cells, CD21high cells and CD23+ cells are decreased in absolute and relative 
numbers in the children with DS. These findings are suggestive of an intrinsic defect 
in B-lymphocyte maturation in the periphery.
 CD21 is the complement type 2 receptor; it has a role in the response to 
polysaccharide antigens like pneumococcal capsular elements. These antigens form a 
complex with CD21 on B-lymphocytes causing a T-cell-independent response. The lower 
response to unconjugated pneumococcal vaccination and the increased rate of 
respiratory infections in DS could be related to this decreased expression of CD21. 
Interestingly, a subgroup of patients with CVID with relatively increased CD21low 
B-lymphocytes is more likely to develop splenomegaly, auto-immune diseases and 
lower respiratory tract infections [26]; the latter two are frequently found in DS as well.
 CD23 is the low-affinity IgE-receptor (FcεRII), it is a ligand of CD21. Together, they 
stimulate B-lymphocyte proliferation and differentiation [27]. CD23-expression is 
increased just before the class-switch from IgM to IgG, IgA or IgE [27]. Besides, CD23 is 
involved in both positive and negative feedback-loops for IgE-homeostasis [27]. 
Interestingly, both asthma incidence (RR 0.4, 95% CI 0.2-0.6) and IgE-levels are 
decreased in DS [28, 29], which is consistent with our findings. Our results suggest 
that increased IgE production is associated with a higher level of CD23 expression in 
children with DS.
 The serum Ig values in children with DS – with or without recurrent infections – 
and non-DS children with recurrent infections are both abnormal, but differ from 
each other. Decreased IgG2 is a well-known abnormality in children with recurrent 
infections; this coincides with our findings in children with DS. However, the increased 
IgG, IgG1, and IgG3, and decreased IgM and IgG4 are found in the children with DS only.
 In conclusion, we found that the humoral immune system is disturbed in children 
with DS. We could not differentiate between an intrinsic B-lymphocyte defect and 
disturbed T-lymphocyte help as the most important cause based on our present data. 
This question remains unanswered, and further studies are needed to solve it. 
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Down syndrome children show a decreased avidity of the antibody response after 
tetanus toxoid booster vaccination at nine years of age suggesting impaired memory 
B cell selection in the germinal center. Clinicians need to be aware of this ongoing 















Children with Down syndrome show abnormal thymocyte maturation and T-lymphocyte 
development [1]. The increased frequency of haematological malignancies and 
auto-immune diseases but absence of opportunistic infections in DS suggests this is 
associated with a clinically relevant but mild T-lymphocyte deficiency [2]. The 
increased, mainly respiratory, infections in especially younger children with DS suggest 
a possible B-lymphocyte problem [3]. Recently, we found a striking B-lymphocytope-
nia in DS [4], and decreased immunoglobulin(Ig)G2, IgG4 and IgM but increased IgG1, 
IgG3 and total IgG serum levels after 5 years of age [3], as had been described before 
[5]. It is not clear whether the low absolute B-lymphocyte numbers and their altered 
Ig-production are mainly caused by an intrinsic B-lymphocyte defect, which would fit 
the increased frequency of respiratory infections in DS [5], or whether these changes 
are mainly accounted for by a T-lymphocyte defect leading to altered T-lymphocyte 
help and impaired T-B-lymphocyte collaboration.
 Assaying specific antibody production against well-defined antigens can be used 
as an in vivo model to assess the capacity of the immune system. The response to 
T-cell dependent antigens represents the combined outcome parameter of 
T-lymphocyte function, T-B interaction and B-lymphocyte function, whereas the 
response to T-cell independent antigens is largely if not only determined by 
B-lymphocyte function alone. Repeated vaccination with a T-cell dependent antigen 
activates selected clones of memory B-cells that produce high avidity immunoglobu-
lins after somatic hypermutation. 
 A strong T-cell-dependent B-lymphocyte response is normally seen after exposure 
to tetanus toxoid (TT), a highly immunogenic protein antigen, with increased avidity 
after repeated boosting [6]. Disturbed responses may be indicative of a clinically 
relevant antibody deficiency. Earlier reports on tetanus vaccination in DS showed the 
ability to achieve the threshold of protective antibody levels at a random time point 
after vaccination, which is set at 0.2 IU/ml (= 1 µg/ml) specific anti-TT-IgG according to 
World Health Organization criteria [7,8]. However, peak anti-TT-responses at 3 to 4 
weeks after booster vaccination and avidity maturation data, which will be disturbed 
in case of impaired T-B interaction processes in the germinal center, have never been 
reported in DS. 
PATIENTS AND METHODS
TT is part of the Dutch immunization program at 2, 3, 4 and 11 months of age, with 
boosters at 4 and 9 years. In a cross-sectional study, paired sera of 22 children with DS 
(4 years of age, n=15; 9 years of age, n=7) were obtained before and 3 to 4 weeks after 
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regular TT-booster at 4 or 9 years of age (1 pre-vaccination serum missing at 4 years of 
age). Specific anti-TT-IgG and IgG-subclasses were measured by an antibody-capture 
enzyme-linked immunosorbent assay [9]. Since the IgG-response after TT-booster in 
healthy controls predominantly (>75%) consists of IgG1 antibodies, the anti-TT 
avidity-ELISA was performed for IgG1 only [9]. Avidity is expressed as the relative index 
representing the molarity of NaSCN required to elute 50% of TT-bound IgG1 [9]. Results 
were compared with reference values obtained in 20 healthy age-matched controls 
(for the children with DS at 4 years of age) and 20 healthy adults (Ad-REF) (for the 
children with DS at 9 years of age), respectively [6]. Statistical analysis was performed 
after logarithmic transformation using the t test and SPSS 16.0 for Windows.
RESULTS
In our DS cohort, 10 of 14 (71%) of the children at 4 years and all 7 children (100%) at 9 
years of age already had protective antibody titers according to the WHO-criteria 
before their TT-booster vaccination. All 22 children with DS (100%) responded to the 
booster vaccination with an increase in antibody titer. Post-vaccination antibody 
formation in DS and controls consisted predominantly of IgG1 (about 75%), as expected. 
However, post-booster vaccination anti-TT-antibody titers (Figure 1a) and IgG1-avidity 
(Figure 1c) were significantly lower in 4-year-old children with DS compared with AMC 
children: anti-TT-total IgG geometric mean titer (GMT) was 58 µg/ml (range 32-164) in 
DS and 178 µg/ml (range, 72-424) in AMC (p<0.001), anti-TT-IgG1 GMT was 45 µg/ml 
(range 17-130) in DS and 131 µg/ml (range, 26-380) in AMC (p<0.001), anti-TT-IgG2 GMT 
was 0.60 µg/ml (range, 0.14-10) in DS and 4.0 µg/ml (range, 0.62-30) in AMC (p<0.001), 
anti-TT-IgG3  GMT was 2.4 µg/ml (range, 0.49-19) in DS and 1.5 µg/ml (range, 0.20-17) 
in AMC (p=0.248) and anti-TT-IgG4 GMT was 0.26 µg/ml (range, 0.02-22) in DS and 2.0 
µg/ml (range, 0.08-21) in AMC (p=0.005) (Figure 1a). IgG1-avidity GMT was 2.5 (range, 
2.2-2.9) in DS and 2.8 (range, 2.6-3.1) in AMC children (p=0.002). The fold increase of 
post- versus pre-booster anti-TT-IgG1 was not significantly different between DS and 
AMC children at 4 years of age.
 After booster vaccination at 9 years of age, anti-TT-antibody total IgG, IgG1, and 
IgG3 GMT (Figure 1b) fall within the adult reference range, but anti-TT-IgG2 GMT and 
anti-TT-IgG4 GMT remained significantly decreased: anti-TT-IgG2 GMT was 0.47 µg/ml 
(range, 0.14-4.5) in DS and 2.3 µg/ml (range, 0.47-24) in Ad-REF (p=0.011), anti-TT-IgG4 
GMT was 0.14 µg/ml (range, 0.03-3.5) in DS and 1.4 µg/ml (range, 0.09-28) in Ad-REF 
(p=0.015). IgG1-avidity (Figure 1c) is still significantly decreased: GMT was 2.7 in DS and 
2.9 (range, 2.7-3.2) in Ad-REF (p=0.006). The fold increase of post- versus prebooster 
anti-TT-antibody titers was not significantly different between DS children at 9 years 














 Conform previous observations in healthy controls [6], there was no correlation 
between the titer and the avidity of anti-TT-IgG1 postvaccination in the children with DS.
Figure 1   Specific anti-TT IgG and IgG-subclasses before and 3-4 weeks after tetanus 
booster vaccination at 4 years (A) and 9 years (B) of age; anti-TT IgG1 avidity 
after tetanus booster vaccination at 4 or 9 years of age (C). anti-TT indicates 
antitetanus toxoid.
IgGt, total anti-TT IgG. Relative avidity index: the molarity of NaSCN required to elute 50% of 
TT-bound IgG1. Open circles: Down syndrome subjects. Horizontal lines: geometric mean Down 
syndrome children (95% CI); Open bars:reference group (+/- 2SD).
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DISCUSSION
We found a decreased anti-TT humoral immune response in a cohort of 22 children 
with DS: IgG and IgG-subclass titers are lower at 4 years of age, and – despite 
normalisation of IgG, IgG1, and IgG3 titers - avidity maturation remains impaired at 9 
years of age. These data show that DS children have lasting difficulties with specific 
anti-TT-antibody formation, although ‘protective levels’ for tetanus toxoid are being 
reached.
 We compared our data to other possibly immunocompromised patient cohorts 
from the literature. Patients with decreased numbers of helper-T-lymphocytes such as 
children with partial DiGeorge syndrome [10] and HIV+ children [11] and adults [9] 
mount a protective response but with lower mean IgG anti-TT-antibody titers. There 
are no pediatric data on antibody avidity, but IgG1-avidity in HIV+ adults was normal 
after TT-booster vaccination [9,11]. The decreased TT-specific IgG1-avidity levels despite 
repeated booster vaccination are suggestive of a subtle impairment of the selection 
process of memory B-cells in the germinal center in DS, which cannot be overcome by 
repeated TT- booster vaccination and maturation of the DS immune system with 
ageing. This is reminiscent of patients with common variable immunodeficiency in 
whom insufficient somatic hypermutation leading to reduced generation of 
high-affinitiy antibodies has been described, associated with an increased frequency 
of severe respiratory tract infections [12,13].  
 Clinicians need to be aware of this ongoing deficiency in antiprotein antibody 
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INFLUENZA A/H1N1 VACCINATION 
RESPONSE IS INADEQUATE IN  
DOWN SYNDROME CHILDREN WHEN THE 
LATEST CUT-OFF VALUES ARE USED
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We determined the response of 48 Down syndrome children to 2 doses of influenza A/
H1N1 vaccination. 92% reached the previously defined protective level (HI titer ≥1:40), 
but only 27% reached the level of ≥1:110 which was recently described to predict the 
conventional 50% clinical protection rate in children. Further studies, and potentially 

















Many children with Down syndrome (DS) suffer from recurrent respiratory infections 
with higher rates of hospitalisation, sepsis and death [1,2]. This can be explained 
by anatomic and functional ear-nose-throat abnormalities, hypotonia, cardiac 
abnormalities, mental retardation and increased incidence of gastroesophageal reflux 
[3,4,5], but also decreased antibody responses to vaccination are seen [6,7,8]. The 
immune response to influenza vaccination in DS has been described as decreased [9] 
or as normal [10].  
 In 2009, the emergence of a new influenza A virus (H1N1) led to a worldwide 
pandemic. Vaccination campaigns were started in response to the expected high 
morbidity and mortality. In the Netherlands, patients with e.g. chronic respiratory, 
cardiac or immunological diseases who normally would be offered an annual seasonal 
influenza vaccine were offered H1N1 vaccination as well.  Also, healthy children aged 
6 months to 4 years were offered two influenza A/H1N1 vaccinations in a nation-wide 
campaign. DS children are not regarded as a risk group for influenza in the Netherlands, 
and therefore are not routinely offered a seasonal influenza vaccine, unless they have 
additional pulmonary or cardiac disease. The 2009 H1N1 vaccination campaign was 
used to measure the antibody response following 2 doses of influenza A/H1N1 in 48 
DS children.
METHODS
Three Dutch hospitals - Jeroen Bosch Hospital in ‘s-Hertogenbosch, Maxima Medical 
Centre in Veldhoven, Elkerliek Hospital in Helmond - included 73 DS children after 
informed parental consent. During routine visits to the outpatient clinic extra blood 
was drawn. Forty-eight blood samples were collected from 48 vaccinated DS children 
(median age 8.8, range 0.7-17 years; 26 boys) with a median of 154 days (range 23-267) 
after two doses of the 2009 influenza A/H1N1 vaccine (monovalent MF59-adjuvant-
ed). A comparison was made with 25 unvaccinated DS children (median age 8.5, range 
0.2-19 years; 17 boys). All assays were performed in the laboratory of the St. Elisabeth 
Hospital in Tilburg, the Netherlands. Virus-specific antibodies were measured by a he-
magglutination-inhibition (HI) assay, using egg-grown A/California/7/2009 A (H1N1) 
pandemic virus and fresh turkey red blood cells in Alsever’s solution (Biotrading, 
Netherlands), according to standard methods [11]. The HI titer was the reciprocal of 
the highest dilution of serum that inhibited virus-induced hemagluttination. Titers 
<10 were assigned a value of 5. Comparison of HI assay data from different laboratories 
is complicated by a lack of standardization due to the use of various influenza virus 
strains, different receptor-destroying enzymes (homemade or commercially bought) 
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and also by differences in quality and nature of red blood cells. Red blood cells and 
receptor-destroying enzyme were bought commercially to overcome this problem and 
a candidate international standard for antibody titers to pandemic H1N1 virus was 
used to calibrate our HI titers [12]. 
 A HI titer of ≥1:40 has been reported to result in a 50% reduction of influenza 
infections in healthy adult individuals [13]. Up to recently, this titer was used as a 
protective cut-off value in children as well. Recently, Black et al [14] challenged this 
cut-off value in healthy children and suggested a new cut-off value of at least ≥1:110 in 
healthy children for a 50% influenza infection reduction.  
RESULTS
HI titers of DS children are shown in figure 1. Ninety-two percent of the 48 vaccinated 
DS children reached a HI titer of ≥1:40. Only 27% of the 48 vaccinated DS children 
reached a HI titer of ≥1:110. In comparison, 28% of unvaccinated DS children reached a 
HI titer of ≥1:40 after the influenza season, and no unvaccinated DS child reached the 
HI titer of ≥1:110.
Figure 1   Hemagglutination-inhibition titer in children with Down syndrome after 
influenza A/H1N1 vaccination.
X-axis: days after second H1N1 vaccination. Y-axis: HI titer (1:y). Dots: Down Syndrome (DS) 
children vaccinated twice with influenza A/H1N1. Triangles: unvaccinated DS children. Horizontal 
















 In one child, parents reported a possible side-effect of fever after the first 
vaccination. In the vaccinated group flu-like symptoms were reported in one child, but 
no influenza tests were performed during that time. In the unvaccinated group four 
children had flu-like symptoms; one child was admitted to hospital (test-results: 
Influenza negative, Respiratory Syncytial virus positive). 
DISCUSSION
Post-vaccination hemagglutination-inhibition titers of ≥1:40 have been reported to 
result in a 50% reduction of influenza infections in healthy adults [13]. Since 92% of 
our 48 vaccinated DS children reached this HI titer after two doses of the 2009 
influenza A/H1N1 vaccine, it would be logical to conclude that this is an effective 
vaccination strategy for DS children. However, this HI cut-off value has not been 
studied for influenza A/H1N1 vaccination in children. Pre-vaccination data from the 
available literature show that up to 30% of healthy children already reach a HI titer of 
≥1:40 without a history of previous influenza A/H1N1 vaccination or active influenza 
A/H1N1 infection [15,16]. Cross-reactive antibodies from other influenza-strains could 
be held accountable, but it seems that this explanation is not entirely valid, as recent 
studies demonstrated no cross-reactivity between antibodies of previous seasonal 
influenza- and H1N1-strains in children [17,18]. 
 The applicability in children of the WHO cut-off value has recently been challenged 
by Black et al. in this journal [14]. They predict a HI titer of ≥1:110 is needed for a 50% 
clinical protection rate in healthy children, at least until 6 years of age. Unfortunately, 
most pediatric publications do not show individual HI titers. In a recent Swiss 
publication [19], post-vaccination HI titers of ≥1:110 were reached in ≥90% of healthy 
children using one dose of influenza A/H1N1 MF59-adjuvanted vaccine. No large 
studies correlating HI titer and clinical protection are as yet available in children.
 Our study shows that DS children only reach the new proposed cut-off value of 
≥1:110 in 27% of the cases studied. This is a lower response than was reported for 
non-DS children, and is another example of decreased immunological vaccination 
response in DS. A larger study is needed to determine the efficacy of clinical protection 
of H1N1 influenza vaccination in DS children.
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Meningococcal serogroup C conjugate (MenC) vaccine is part of the Dutch 
immunization program since 2002.  In the MenC vaccine, the polysaccharide antigen 
is linked to the protein carrier tetanus toxoid with the aim to achieve an adequate 
immune response at an early age, which would not be possible with a pure poly- 
saccharide vaccine. The immune response to a conjugate vaccine is characterized by 
T-cell-dependent isotype-switching to IgG-antibodies, especially IgG1, and induction 
of immunological memory. 
METHODS
In a catch-up campaign, all children (1-18 years) were offered a single dose of MenC in 
the Netherlands in 2002. Blood samples of 19 Down syndrome (DS) children (mean 
age 10.6, range 5.3-17.4 years) were taken during regular hospital visits 3 months (n=7; 
mean 13 weeks, range 39-107 days), or around 1 year (n=12; mean 50 weeks, range 
275-447 days), after this single dose of MenC vaccination. MenC polysaccharide (PS) 
specific IgG, IgM and IgA levels were measured using an antibody-capture enzyme- 
linked immunosorbent assay.1 Results were compared with reference values of healthy 
adults from the same laboratory, 1 month (n=12) and 1 year (n=11) after single MenC 
vaccination. 
RESULTS
At 3 months post-vaccination, geometric mean MenC/PS specific IgG, IgA and IgM 
serum levels were 5.5 (range 1.4-41), 0.71 (0.03-11) and 0.61 (0.10-7.5) µg/mL, compared 
to 26 (5.6-59), 5.6 (2.1-11) and 5.2 (1.7-35) µg/mL in healthy controls (p= 0.014, 0.028, 0.12 
assessed by Mann-Whitney test respectively). One year after vaccination, geometric 
mean MenC/PS specific IgG, IgA, and IgM levels were 2.7 (0.78-15), 0.19 (0.02-1.2) and 
0.28 (0.15-0.76) µg/mL, whereas reference values were 4.5 (0.68-19), 0.79 (0.13-3.8), 
and 0.71 (0.16-5.1) µg/mL (p= 0.204, 0.019, <0.001 assessed by Mann-Whitney test 
respectively). The 19 DS children did reach protective, but lower levels after a single 
MenC vaccination in comparison to healthy adults, despite the fact that 9 of them 
showed hypergammaglobulinemia according to age-matched reference values.2
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CONCLUSIONS
Assaying specific antibody production against well-defined antigens can be used as 
a model to assess T-cell-dependent (anti-protein) and T-cell-independent (anti-poly-
saccharide) antibody responses; conjugated protein-polysaccharide vaccines like 
MenC show aspects of both types of responses. Impaired specific antibody responses 
to unconjugated pneumococcal polysaccharide have been described in DS, suggesting 
a B-lymphocyte problem.3 Impaired responses to influenza, hepatitis B and tetanus 
(protein-prototype) have been described as well, suggesting an additional T-lymphocyte 
or T-B-interaction problem.3 Not unexpectedly therefore, our data show that protein 
conjugation does not fully overcome the impaired antibody production to this 
polysaccharide antigen in DS. 
 Of course, decreased antibody production upon vaccination may have clinical 
implications as well. DS children have frequent respiratory infections, but an increased 
frequency of meningococcal disease has not been described in recent surveys, either 
in the pre-4 or post-MenC5 era, but specific attention was not given to this subject. 
So, it is as yet unclear whether children with Down syndrome are at greater risk of 
meningococcal disease, or whether they would benefit from an additional dose of 
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FUNCTIONALITY OF THE  
PNEUMOCOCCAL ANTIBODY RESPONSE  
IN DOWN SYNDROME SUBJECTS





We investigated the anti-polysaccharide antibody responses in subjects with Down 
syndrome (DS) because DS subjects show decreased peripheral B-lymphocyte 
numbers in all age groups, and a clinical picture of recurrent respiratory tract infections 
and increased incidence of autoimmune diseases which is reminiscent of common 
variable immunodeficiency disorders (CVID)-like disease. We determined titers and 
opsonophagocytosis in response to conjugated and unconjugated pneumococcal 
serotypes in 18 DS subjects aged 6 to 24 years. The results show adequate sero-
type-specific antibody titers in response to all conjugated and almost all unconjugated 
serotypes used. Opsonophagocytosis activity as measured against pneumococcal 
serotypes 9N, 19F and 23F was also found to be  intact. We conclude that DS subjects 
















Down syndrome, or trisomy 21, is a relatively common chromosomal disorder 
(incidence 1:800) [1] associated with a variety of immunological abnormalities 
including abnormal thymocyte maturation and T-lymphocyte development [2], and a 
striking B-lymphocytopenia [3] with decreased immunoglobulin(Ig)G2 and IgG4 and 
increased total IgG-serum levels after 5 years of age [4]. Lower specific antibody 
responses have been reported: the antibody response [5] and avidity maturation after 
tetanus toxoid booster [6] is impaired, the antibody responses to hepatitis B 
vaccination [7] and the hemagglutination-inhibition titer to influenza A/H1N1 
vaccination [7,8] are decreased. 
 DS subjects have an increased incidence of mainly respiratory infections [9,10], 
which are often caused by Streptococcus pneumoniae, a polysaccharide-encapsulated 
bacterium. This might be related to a (subtle) antibody deficiency. However, the 
frequent infections may also be – at least partially – explained by the facial anatomy, 
chronic Eustachian tube dysfunction, and hypotonia in DS as well [10,11]. 
 An adequate immune response to S. pneumoniae depends on the production of 
serotype-specific antibodies, but in particular on the functionality of these antibodies 
(opsonophagocytosis). Younger children are not yet able to produce anti-polysaccha-
ride antibodies; protein-conjugated vaccines are used to overcome the effects of this 
physiological immaturity of the anti-polysaccharide antibody response in infants. 
Specific anti-polysaccharide antibody deficiency (SPAD) is a well-known milder 
antibody deficiency in non-DS older children and adults [14], which may lead to an 
increased frequency of respiratory infections. 
The antibody response to the unconjugated 23-valent polysaccharide pneumococcal 
vaccine was reported lower but not deficient in DS by Costa-Carvalho et al. [12] and 
Nurmi et al. [13] after a single vaccination as compared to healthy controls in children 
>6 years [12] and adults [13], respectively. It has not yet been established whether 
DS subjects react normally to protein-conjugated pneumococcal vaccinations, which 
are now part of the regular immunisation scheme in many countries. Adequate 
pneumococcal vaccination could be clinically relevant because of the tendency in DS 
towards recurrent respiratory tract infections. Until now, DS infants are offered the 
same immunisation schedule for pneumococci as healthy infants, a scheme generally 
containing four doses (3+1) of a conjugated pneumococcal vaccine. In the Netherlands, 
the 7-valent conjugated pneumococcal vaccine Prevnar® (PCV-7) was introduced in 
the national immunisation program for infants born after April 2006. As of March 2011, 
it has been replaced by the 10-valent conjugated pneumococcal vaccine Synflorix®.
 Given the immunological disturbances and clinical phenotype in DS, it is attractive 
to hypothesize that SPAD could – at least in part – explain the recurrent respiratory 
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infections in DS. We investigated this using polysaccharide and conjugated 
pneumococcal vaccines, which are prototypes for T-cell independent (TI) anti-poly-
saccharide and T-cell dependent (TD) combined anti-protein and anti-polysaccharide 
antibody responses, respectively.
 We used a vaccination scheme with conjugated followed by polysaccharide 
pneumococcal vaccine in 18 DS subjects. The response to polysaccharide vaccine only 
serotypes were used to analyze whether SPAD is an integral feature of the DS immune 
system. The combined polysaccharide / conjugated vaccine serotypes were used to 
analyze whether SPAD, if found, can be overcome by protein-conjugated vaccination. 
The study was restricted to participants >5 years of age, because young children would 
be expected to show a physiological ‘SPAD’ anyway.
 Results from non-DS healthy adults and non-DS children with recurrent – mainly 
respiratory – infections without serious primary immunodeficiency were used to 
compare the serotype-specific pneumococcal antibody response profiles.
MATERIAL AND METHODS 
This study was approved by the local Medical Ethical Committee, and was performed in 
2009 and 2010 in the Jeroen Bosch Hospital, ‘s-Hertogenbosch, the Netherlands. 
These subjects were born before 2006, before the introduction of pneumococcal 
vaccination in the national Dutch immunisation program. Eighteen non-institutional-
ized Dutch DS subjects >5 years of age who had never received a pneumococcal 
vaccine were included after parental informed consent (median age at inclusion 12 
years, range 6-24 years; 10 female, 3 subjects aged >18 years). Data on the history of 
infections, and incidence of autoimmune diseases and malignancies were collected 
from the medical files and verified with the parents. 
 DS subjects were vaccinated twice with a heptavalent pneumococcal conjugate 
vaccine (PCV-7; Prevnar®, Wyeth, Rochester, NY, USA) at t=0 and t=4 weeks, followed 
by a single vaccination with a 23-valent pneumococcal polysaccharide vaccine (PPV-23; 
Pneumo23®, Pasteur-Merieux, Lyon, France) at t=12 weeks. PCV-7 contains 2µg of 
serotype 4, 9V, 14, 19F and 23F polysaccharide, 4µg of serotype 6B polysaccharide, and 
2µg of serotype 18C oligosaccharide, each conjugated individually to the CRM197 
protein. PPV-23 contains 25µg of serotype 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 
15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F polysaccharide. Blood samples were taken 
before the first and four weeks after the last vaccination. Serum samples were stored 
at –20 ºC until further analysis.
 Anti-pneumococcal IgG-antibodies against pneumococcal serotypes 1, 3, 7F, 8, 9N, 
12F, and 19A (PPV-23 only) and serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F (both PPV-23 and 















TX, USA) according to the manufacturer’s instructions [18]. Data are presented as 
individual IgG-antibody titers (µg/ml) to each of the fourteen pneumococcal serotypes 
tested. 
 For the prevention of invasive pneumococcal disease (IPD) in children a cut-off 
value of ≥0.35µg/ml was agreed upon by the WHO [15]. For the prevention of mucosal 
infection in children after pneumococcal vaccines a higher cut-off value of ≥1.0µg/ml 
has been suggested [16,17]. In the data analysis we used this higher cut-off value 
because an important goal in DS children would also be the prevention of their 
recurrent respiratory tract infections.
 Antibody titers to serotype 3 (PPV-23-only) were compared to single-PPV23 
vaccinated healthy adults (n=15, median age 42 years, range 22-69 years) and children 
with recurrent respiratory infections but without serious primary immunodeficiency 
(n=17; median age 6 years, range 2-18 years). Antibody titers to serotype 1, 7F, 8, 9N, 12F, 
and 19A (PPV-23-only) were compared to single-PPV-23 vaccinated children with 
recurrent respiratory infections (n=14; 3 missing due to insufficient amount of serum) 
from the same laboratory and to single PPV-23 vaccinated healthy Belgian adults 
(n=40; mean age 21 years, range 19-30 years) [19] and children (n=35, mean age 
8 years, range 3-15 years) [19] and Belgian elderly (n=58, mean age 76 years, range 
58-92 years) [20] from the literature using the same multiplex bead-based assay.
 Antibody titers to serotype 4, 6B, 9V, 14, 18C, 19F, and 23F (both PCV-7 and PPV-23 
serotypes) were compared to English children with recurrent infections but without 
serious primary immunodeficiency who underwent the same combined vaccination 
schedule using the same multiplex bead-based assay (n=25; median age 5 years, range 
2-16 years; original data kindly provided by R. Borrow) [21].
 Opsonophagocytosis assays (OPAs) for serotype 9N (PPV-23-only), 19F and 23F 
(both PPV-23 and PCV-7) were performed in DS subjects and single-PPV-23 vaccinated 
children with recurrent respiratory infections from the same laboratory. These three 
serotypes were chosen because the DS subjects responded with low (9N, 
unconjugated), medium (19F, conjugated) and high (23F, conjugated vaccine) antibody 
titers to these serotypes. A minimum antibody titer of 0.35µg/ml is needed for this 
OPA. In brief, serum samples (100µl) were diluted in antibody depleted human serum 
(ADHS) to a final concentration of 0.35µg/ml. S. pneumoniae strains of serotype 9N, 
19F and 23F were cultured, labeled with fluorescein isothiocyanate (FITC), and adjusted 
to a concentration of 2.5 x 108/ml. Equal volumes of FITC-labeled pneumococci were 
added to the sera. Peripheral blood granulocytes, obtained from healthy adult 
volunteers, were prepared by osmotic lysis of whole blood. A suspension of 5 x 106 
granulocytes per ml was prepared in Roswell Park Memorial Institute medium (RPMI 
1640 + GlutaMax T -I, 1x 0.1% Clindamycin) + 10% fetal calf serum. Opsonized 
pneumococci and 100µl granulocytes were incubated for 15 minutes at 37˚C; 
incubation was stopped by addition of ice-cold phosphate-buffered saline. Cells were 
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washed twice with cold RPMI and measured on a fluorescence-activated cell sorting 
(FACS) Calibur flow cytometer (Becton Dickinson, San Jose, CA).  From each sample, 
10,000 cells were measured and the FITC fluorescence intensity of the gated 
granulocytes was used as parameter for phagocytosis. Data are expressed as 
phagocytosis index. The phagocytosis index (PI) is the percentage of granulocytes 
that have phagocytized multiplied by the mean fluorescence intensity (MFI). 
 All concentrations of anti-pneumococcal IgG-antibodies pre- and post-vaccination 
and OPA titers were transformed by the logarithmic function. Differences in antibody 
response and OPA titers between groups were evaluated by the Welch t test. A p-value 
of <0.05 was considered statistically significant.
RESULTS
The clinical characteristics of the DS subjects are listed in Table 1. DS anti-pneumococcal 
IgG-antibodies pre- and post-vaccination are shown in Table 2. Post-vaccination 
IgG-antibodies of all non-DS groups (see Methods) are shown in Table 2 as well. Table 3 
shows the percentage with a seroprotective response (cut-off value ≥1.0µg/ml) for 
each serotype in DS subjects and non-DS subjects (healthy adults, and children with 
recurrent infections from the same laboratory, and children with recurrent infections 
[21], original data kindly provided by R. Borrow). Post-vaccination anti-pneumococcal 
IgG-antibodies of DS subjects and English children with recurrent infections [21] 
undergoing the same vaccination scheme are shown in Figure 1. The OPA results for 
the DS subjects and the non-DS subjects with recurrent respiratory infections (but 
without serious primary immunodeficiency) are shown in Figure 2. 
Table 1   Clinical features of Down syndrome subjects.
Total
(n=18)
No recurrent infections 4 (24%)
History of recurrent respiratory infections 14 (78%)
Recurrent respiratory infections > 6 years 8 (44%)
Celiac disease 3 (17%)
Auto-immune hypothyroidism 4 (22%)









































































































































































































Anti-pneumococcal IgG titers: DS subjects
Post-vaccination anti-pneumococcal IgG-antibodies were significantly higher (p<0.001) 
than the pre-vaccination IgG-antibodies in all DS subjects. 
T-cell independent (TI) antibody responses (PPV-23-only) 
67% (12/18) of the DS subjects reached ≥1.0µg/ml of anti-pneumococcal IgG-antibodies 
in response to serotype 3, a highly immunogenic serotype. All DS subjects reached 
≥1.0µg/ml post-vaccination anti-pneumococcal IgG-antibodies in response to sero - 
types 1, 7F, 8, and 19A; 83% reached this value for serotype 9N and 39% for serotype 12F. 
Table 2   Anti-pneumococcal IgG titers in subjects with DS compared to healthy  
children and adults and children with recurrent infections.
Down syndrome subjects 
(N=18)








(N=25)        






2x PCV-7 and 1x PPV-23 1x PPV-23 1x PPV-23 2x PCV-7 and 1x PPV-23 1x PPV-23 1x PPV-23
Serotypes Pre-GMT        Post-GMT    Post-GMT   Post-GMT   Post-GMT Post-GMT Post-GMT    
PS3 0.27 (0.09-0.60) 1.7 (0.80-4.8) 1.4 (0.50-3.0) 1.7 (0.91-3.9) 1.8 (0.67-3.1) 2.1 (1.2-4.1) 1.2 (0.60-4.6)
PS1 0.63 (0.54-0.92) 2.5 (1.7-3.8) - 3.0 (2.0-5.9) 0.33 (0.10-0.94)* 2.5 (1.3-5.0) 2.4 (0.95-6.3)
PS7F 1.5 (1.0-2.4) 4.3 (2.9-5.7) - 3.8 (1.9-7.1) 0.82 (0.25-2.0)* 6.5 (3.7-14)* 19 (3.2-19)*
PS8 0.67 (0.36-1.3) 6.6 (3.5-13.6) - 8.7 (7.7-15) - 7.1 (3.1-10) 2.9 (1.7-9.2)
PS9N 0.34 (0.15-0.84) 1.7 (1.2-2.3) - 3.4 (2.5-8.0)* - 4.8 (2.3-10)* 10 (2.9-11)*
PS12F 0.40 (0.33-0.54) 1.0 (0.65-1.3) - 1.9 (1.2-3.7)* - 1.2 (0.70-2.2) 1.9 (1.0-5.8)*
PS19A 1.6 (0.70-4.3) 5.3 (2.4-9.1) - 4.5 (2.7-7.1) 0.89 (0.27-1.4)* 3.8 (2.1-9.2) 9.2 (6.4-9.2)
PS4 0.10 (0.07-0.17) 3.7 (1.3-12) 1.0 (0.36-2.2) 2.9 (1.7-6.8) 2.3 (0.85-7.8) 3.3 (1.4-6.6) 1.9 (0.66-5.3)
PS6B 0.13 (0.04-0.30) 3.1 (1.1-6.7) 1.6 (0.39-4.9) 1.2 (0.63-2.6) 1.5 (0.69-4.6) 3.9 (1.8-10) 6.8 (1.8-17)
PS9V 0.11 (0.09-0.18) 2.1 (0.95-5.4) 2.6 (0.68-13) 1.6 (0.76-5.2) 1.7 (0.95-4.7) 2.8 (1.4-7.7) 8.4 (1.9-9.0)
PS14 0.89 (0.34-0.83) 14 (4.7-44) 6.0 (2.6-13) 3.2 (0.69-14) 3.4 (1.7-8.8)* 11 (2.5-20) 20 (5.5-20)
PS18C 0.15 (0.09-0.21) 4.0 (2.6-11) 3.8 (1.9-5.2) 2.8 (1.8-5.1) 2.9 (1.8-7.9) 3.3 (1.1-8.7) 11 (4.3-12)
PS19F 0.12 (0.05-0.21) 2.8 (1.2-4.8) 4.0 (2.0-11) 2.5 (1.1-9.4) 4.4 (2.0-9.4) 6.5 (2.6-12) 8.4 (2.6-12)
PS23F 0.28 (0.15-0.66) 7.9 (2.3-21) 1.7 (0.93-2.7) 1.1 (0.62-2.2) 2.6 (1.3-5.9)* 2.5 (1.0-6.3) 3.8 (1.5-6.4)
GMT: Geometric mean antibody titer (µg/ml), 25th and 75th percentile between brackets; PS: pneumococcal 
serotype; PPV23-only serotypes (bold) and PPV23/PCV7 serotypes (Italic). * = significant (p<0.05) difference 
GMT DS group versus healthy adults or children with recurrent infections (statistics for PCV7 serotypes only 















 T-cell independent antibody responses in DS subjects for PPV-23-only serotypes 
(serotypes 1, 3, 7F, 8, 9N, 12F and 19A) were compared with healthy adults and elderly, 
and children with recurrent infections without serious primary immunodeficiency. 
The DS subjects showed a similar post-vaccination response to serotype 3 as healthy 
individuals and children with recurrent infections (Table 2, no significant difference). 
In comparison to healthy individuals [19,20], DS subjects showed a similar anti- 
pneumococcal IgG response to serotypes 1, 8, and 19A, but a lower response to 
serotypes 7F, 9N and 12F (Table 2). DS subjects had a significantly lower post-vaccination 
response to serotype 9N and 12F (p=0.024 and p=0.048, respectively) compared to 
Table 2   Anti-pneumococcal IgG titers in subjects with DS compared to healthy  
children and adults and children with recurrent infections.
Down syndrome subjects 
(N=18)








(N=25)        






2x PCV-7 and 1x PPV-23 1x PPV-23 1x PPV-23 2x PCV-7 and 1x PPV-23 1x PPV-23 1x PPV-23
Serotypes Pre-GMT        Post-GMT    Post-GMT   Post-GMT   Post-GMT Post-GMT Post-GMT    
PS3 0.27 (0.09-0.60) 1.7 (0.80-4.8) 1.4 (0.50-3.0) 1.7 (0.91-3.9) 1.8 (0.67-3.1) 2.1 (1.2-4.1) 1.2 (0.60-4.6)
PS1 0.63 (0.54-0.92) 2.5 (1.7-3.8) - 3.0 (2.0-5.9) 0.33 (0.10-0.94)* 2.5 (1.3-5.0) 2.4 (0.95-6.3)
PS7F 1.5 (1.0-2.4) 4.3 (2.9-5.7) - 3.8 (1.9-7.1) 0.82 (0.25-2.0)* 6.5 (3.7-14)* 19 (3.2-19)*
PS8 0.67 (0.36-1.3) 6.6 (3.5-13.6) - 8.7 (7.7-15) - 7.1 (3.1-10) 2.9 (1.7-9.2)
PS9N 0.34 (0.15-0.84) 1.7 (1.2-2.3) - 3.4 (2.5-8.0)* - 4.8 (2.3-10)* 10 (2.9-11)*
PS12F 0.40 (0.33-0.54) 1.0 (0.65-1.3) - 1.9 (1.2-3.7)* - 1.2 (0.70-2.2) 1.9 (1.0-5.8)*
PS19A 1.6 (0.70-4.3) 5.3 (2.4-9.1) - 4.5 (2.7-7.1) 0.89 (0.27-1.4)* 3.8 (2.1-9.2) 9.2 (6.4-9.2)
PS4 0.10 (0.07-0.17) 3.7 (1.3-12) 1.0 (0.36-2.2) 2.9 (1.7-6.8) 2.3 (0.85-7.8) 3.3 (1.4-6.6) 1.9 (0.66-5.3)
PS6B 0.13 (0.04-0.30) 3.1 (1.1-6.7) 1.6 (0.39-4.9) 1.2 (0.63-2.6) 1.5 (0.69-4.6) 3.9 (1.8-10) 6.8 (1.8-17)
PS9V 0.11 (0.09-0.18) 2.1 (0.95-5.4) 2.6 (0.68-13) 1.6 (0.76-5.2) 1.7 (0.95-4.7) 2.8 (1.4-7.7) 8.4 (1.9-9.0)
PS14 0.89 (0.34-0.83) 14 (4.7-44) 6.0 (2.6-13) 3.2 (0.69-14) 3.4 (1.7-8.8)* 11 (2.5-20) 20 (5.5-20)
PS18C 0.15 (0.09-0.21) 4.0 (2.6-11) 3.8 (1.9-5.2) 2.8 (1.8-5.1) 2.9 (1.8-7.9) 3.3 (1.1-8.7) 11 (4.3-12)
PS19F 0.12 (0.05-0.21) 2.8 (1.2-4.8) 4.0 (2.0-11) 2.5 (1.1-9.4) 4.4 (2.0-9.4) 6.5 (2.6-12) 8.4 (2.6-12)
PS23F 0.28 (0.15-0.66) 7.9 (2.3-21) 1.7 (0.93-2.7) 1.1 (0.62-2.2) 2.6 (1.3-5.9)* 2.5 (1.0-6.3) 3.8 (1.5-6.4)
GMT: Geometric mean antibody titer (µg/ml), 25th and 75th percentile between brackets; PS: pneumococcal 
serotype; PPV23-only serotypes (bold) and PPV23/PCV7 serotypes (Italic). * = significant (p<0.05) difference 
GMT DS group versus healthy adults or children with recurrent infections (statistics for PCV7 serotypes only 
applied for children with recurrent infections using the same vaccination scheme).
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children with recurrent infections from the same laboratory. In comparison to English 
children with recurrent infections [21], DS subjects showed a significantly higher 
post-vaccination response to serotype 1, 7F and 19A (p<0.001, p=0.003 and p=0.019, 
respectively; original data kindly provided by R. Borrow). 
T-cell dependent (TD) responses
61% and 89% of the DS subjects reached post-vaccination anti-pneumococcal IgG 
≥1.0µg/ml to ≥6 and to ≥4 PCV-7-serotypes, respectively.  T-cell dependent antibody 
responses in DS subjects for PCV-7 serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) were 
compared with English children [21] undergoing the same vaccination scheme (Table 2, 
Figure 1; original data kindly provided by R. Borrow). DS subjects showed comparable 
responses to all PCV-7 serotypes (no significant difference), except for serotype 14 and 
serotype 23F, which were significantly higher in the DS subjects (respectively p=0.009 
and p=0.049). 
















2x PCV-7 and  
1x PPV-23
1x PPV-23 1x PPV-23 2x PCV-7 and  
1x PPV-23
PS1 100% 88%* - 25%
PS3 67% 65% 60% 64%
PS7F 100% 86% - 45%
PS8 100% 93% - -
PS9N 83% 86% - -
PS12F 39% 86% - -
PS19A 100% 86% - 36%
PS4 83% 88% 53% 76%
PS6B 78% 65% 53% 68%
PS9V 72% 76% 67% 76%
PS14 100% 71% 93% 84%
PS18C 83% 94% 93% 84%
PS19F 78% 82% 87% 92%
PS23F 78% 71% 71% 79%
















OPA results for serotype 9N (PPV-23 only) were higher in the DS group compared to 
children with recurrent infections, but this difference was no longer significant after 
logarithmic transformation (p=0.058). OPA results for serotype 23F (both PCV-7 and 
PPV-23) were comparable in both groups (no significant difference). No specific 
relation could be found between DS children suffering from recurrent respiratory 
infections and lower OPA titers to serotype 9N, 19F and 23F (Figure 2).
DISCUSSION
We found the titers of the anti-pneumococcal antibody response to be adequate for 
protection in the studied DS subjects. Their protein-conjugated T-lymphocyte-dependent 
combined PCV-7/PPV-23 responses were within the normal range. Despite the lower 
absolute B-lymphocyte count in DS [3,4], post-vaccination titers of T-lymphocyte- 
independent anti-polysaccharide PPV-23-only responses were not lower in comparison 
to healthy non-DS subjects. Functionality of the antibodies was adequate as well; the 
DS subjects responded with similar OPA titers to serotype 19F and 23F after repeated 
PCV7 or PCV13 vaccinations.
 Why then do many DS subjects suffer from recurrent upper respiratory tract 
infections? And why do these recurrent infections subside after their first 6-8 years of 
Figure 2   Opsonophagocytic assay.
Phagocytosis index (PI) post-vaccination to pneumoccal serotypes 9N, 19F and 23F; Geometric 
mean, logarithmic scale. DS= Down syndrome subjects (9N, 19F, 23F); RI= children with recurrent 
respiratory infections but without serious primary immunodeficiency (9N, 23F).
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life? Well-known ear-nose-throat anatomical abnormalities in DS could be the cause 
for these respiratory infections [26,27,28]. However, these characteristic facial features 
remain the same with increasing age. An explanation could be that the humoral 
immune system in DS reaches an adequate maturation level after repeated antigen 
contact, as shown by us in this study, which protects against ongoing respiratory 
infections. Autoimmune diseases and hematological malignancies, on the other hand, 
increase with increasing age in DS [28]. Continuous infectious pressure on the DS 
immune system due to the intrinsic anatomical abnormalities could be a factor in the 
evolvement of this immunodysregulation: ongoing bacterial infections can lead to 
antibodies that cross-react with host tissue [29]. Then, with time the somatic 
hypermutation process, combined with selection by antigen, will result in high affinity 
antibodies, potentially also with specificity for autoantigens. 
 Our study is limited by the comparison of the results of our DS cohort with those 
obtained in other studies. However, in order to overcome potential differences we 
only included data obtained by the same multiplex bead based assay we used, because 
Borgers et al [19] showed that the serotype 3 titer does not show a good correlation 
between the multiplex bead-assay and the enzyme linked immunosorbent assay 
(ELISA) used in other studies. 
 The strength of our study is the inclusion of an opsonophagocytosis assay for 
affinity maturation after repeated priming. The repeated vaccination scheme we used 
showed production of high-affinity antibodies in the DS subjects comparable to healthy 
children [23], implying an adequate cooperation between B- and T-lymphocytes. In 
comparison, elderly subjects respond to pneumococcal vaccinations with lower 
affinity antibodies [22]. 
 In conclusion, our DS subjects showed an adequate quantitative and qualitative 
immune response to PPV23 as well as PCV7 vaccines, clearly different from the profiles 
of immunosenescence or CVID. The DS subjects did not show signs of SPAD either 
[24,25]. 
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Down syndrome (DS) is the most frequent cause of mental retardation in man.[1] The 
triad of increased incidence of infections, autoimmune diseases and haematological 
malignancies has led to the hypothesis of an altered adaptive immune system in 
Down syndrome.[2-7] During corrective heart surgery it was noticed that the 
macroscopic aspect of the DS thymus looked different.[8] As a result, immunological 
research in DS focused on the thymus and T-lymphocyte problems since the 1970s. 
Early occurrence of Alzheimer disease led to a hypothesis of precocious ageing in 
Down syndrome; until now, the observed clinical profile has been interpreted in the 
same context as premature immunosenescence of the thymus and T-lymphocytes.
[9-12]
 This thesis gives more insight in the qualitative and quantitative alterations found 
in the adaptive immune system of children with Down syndrome. In Part 1 the analysis 
of both T- and B-lymphocyte subpopulations and immunoglobulin (IgG, IgA, IgM) 
levels in different age groups in DS children is described. In Part 2 the quantity and 
quality of B- and T-lymphocyte responses to different types of antigen is investigated 
through vaccination studies, as models for T-lymphocyte dependent (TD) and 





























T- and B-lymphocytes subpopulations in peripheral blood
In chapter 4 we describe low naive T-lymphocyte counts in DS peripheral blood. Our 
study on T-lymphocyte subpopulations in Down syndrome shows that the normal 
expansion of naive helper-T (Th) and cytotoxic-T (Tc)-lymphocytes is lacking from the 
first years of life onwards. Especially naive helper-T-lymphocytes are decreased: e.g. in 
DS children aged 9-15 months median absolute numbers of naive Th are 0.91 x 109 
cells/l as compared to 2.7 x 109 cells/l in age-matched control children (AMC).[13] 
 Decreased numbers of T-lymphocytes from an early age onwards can be the result 
of (partial) failure of thymic output of T-lymphocytes, (partial) failure of proliferation, 
increased apoptosis or a combination of these processes. Thymic anatomical alterations 
are well-known in DS and are already seen in DS fetuses. An impaired thymic output 
with reduced TREC counts in DS has been described.[14-17] 
 Thymic hypoplasia with reduced thymic output is an intrinsic feature of children 
with DiGeorge syndrome (DGS). These children show some similarities to DS children: 
they have a clinical picture of recurrent infections and higher incidence of autoimmune 
disease as well. In DGS, despite thymic hypoplasia, most subjects appear to gradually 
reach T-lymphocyte levels of healthy adults over time, and T-cell function seems 
relatively preserved in most cases in DGS.[18-20] Although the absolute numbers of 
cytotoxic-T-lymphocyte subpopulations in DS also approach age-matched control 
levels towards adulthood, low absolute counts of helper-T-lymphocytes continue to 
be present in all DS age groups. 
 Partial thymectomy during heart surgery in the first year of life can induce thymic 
hypoplasia and decrease thymic output. About fifty percent of DS children also suffer 
from congenital heart disease (CHD). However, non-DS children that undergo early 
CHD-surgery show a gradual recovery towards normal T-lymphocyte levels and 
normal function of T-lymphocytes.[21-23] 
 In chapter 4 we show that T-lymphocytes in Down syndrome children lack the 
proliferative expansion seen in normal children in their first years of life. Exposure to a 
diversity of antigens in the first years of life normally results in an enormous 
antigen-driven expansion of T- and B-lymphocytes in healthy children.[24-26] DS 
children often suffer prolonged and repeated respiratory infections due to their 
unfavorable upper and lower airway anatomy.[27] In a normal immune system, this 
would likely result in increased instead of decreased numbers of lymphocytes. It is 
likely that the DS T-lymphocytes eventually harbor a restricted repertoire, having 
shown such a profound lack of antigen-driven expansion in earlier years. Functional 
impairment in DS T-lymphocytes with decreased proliferative and antigen T-cell 
responses have been described which support this hypothesis.[15, 28-30] For instance, 
the in vitro proliferative response to phytohemagglutinin (PHA) is markedly below 
normal in DS infants as well as DS adults.[30-33] The clinical picture does not fit severe 
T-lymphocyte deficiency, however: DS subjects do not suffer from opportunistic 
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infections or severe failure to thrive. Our findings in chapter 4 do not support severe 
immunodeficiency either: cytomegalovirus (CMV)-seropositive DS children show 
similar absolute numbers (median 0.079 x 109 cells/l) of terminally differentiated 
(CD27-CD45RA+) cytotoxic-T-lymphocytes when compared to healthy children (median 
0.067 x 109 cells/l), not increased absolute numbers as are described in children with 
primary CMV infections during immunosuppressive therapy (0.413 x 109 cells/l) or 
HIV-1 infection (0.369 x 109 cells/l). [34-36] 
 Enhanced cell death by apoptosis could play an extra role in DS besides decreased 
T-lymphocyte production and proliferation. Apoptosis data in DS is scarce and seems 
contradictive: increased telomere shortening is found in DS T-lymphocytes, which 
could lead to higher apoptosis rates.  [37, 38]  A recent study [39] however did not find 
increased apoptosis in peripheral T-lymphocytes, despite increased apoptosis markers 
on T-lymphocytes in earlier reports.[38, 40, 41]
 So, decreased numbers and impaired functioning of T-lymphocytes in Down 
syndrome from an early age onwards seem to be the consequence of combined partial 
failure of thymic output and T-lymphocyte proliferation; apoptosis data is inconclusive.
In chapter 5 we describe the B-lymphocyte subpopulations in the cohort of 95 DS 
children. We found that, apart from their T-lymphocyte alterations, children with 
Down syndrome show alterations in their B-lymphocyte subpopulations as well. Our 
data in chapter 5 show a profound B-lymphocytopenia in all DS age groups: e.g. the 
median absolute numbers of naive B-lymphocytes in the DS age group 9-15 months is 
0.35 x 109 cells/l versus 1.07 x 109 cells/l in AMC; in the DS age group 15-24 months it is 
0.17 x 109 cells/l versus 0.58 x 109 cells/l in AMC. DiGeorge syndrome subjects do not 
have an intrinsic B-cell defect next to their T-cell defect.[42] Recent studies support 
the hypothesis of an impaired B-lymphocyte production in the bone marrow with 
decreased B-lymphocyte output from birth in DS.[42, 43] 
 The majority of B-lymphocyte maturation and development in the periphery is 
T-cell dependent and takes place in the germinal centers. The most important 
B-lymphocyte product IgG is produced by CD27-IgG+ and CD27+IgG+ memory 
B-lymphocytes. It is most likely that CD27+IgG+ B-lymphocytes start out as CD27-IgG+ 
B-lymphocytes; CD27+IgG+ B-lymphocytes result from multiple consecutive germinal 
center reactions with increased proliferation and SHM levels. These B-lymphocytes 
show dominant use of IgG1 and IgG2 in comparison to CD27-IgG+ B-lymphocytes - 
produced in the primary GC reaction - with dominant use of IgG1 and IgG3. Apart 
from low naive B-lymphocytes, we describe a consistently decreased number of 
CD27+-memory B-lymphocytes in all DS age groups. Despite this B-lymphocytopenia, 
DS children show a hypergammaglobulinemia with increased total IgG, IgG1 and IgG3 
(but decreased IgM, IgG2 and IgG4 and normal IgA) serum levels from the age of three 





























globulinemia found in DS is suggestive of dysregulation in class switching   of 
B-lymphocytes within the germinal centers. It might be that memory B-lymphocyte 
proliferation is skewed with a preference towards B-lymphocytes with dominant use 
of IgG1 and IgG3 in primary and secondary germinal center reactions in DS. 
 We also found decreased absolute and relative numbers of CD21high and 
CD23+-B-lymphocytes in DS. CD23 is a ligand of CD21; together they stimulate 
B-lymphocyte proliferation and differentiation. CD21 is the complement type 2 
receptor; it has a role in the response to polysaccharide antigens like pneumococcal 
capsular elements. Median absolute numbers of CD23+- and CD21high-B-lymphocytes 
in DS are around one-third lower in all age groups. The highest expression of CD21 on 
B-lymphocytes is normally found in the splenic marginal zone (CD27+IgM+IgD+) on 
natural effector B-lymphocytes. Natural effector B-lymphocytes play an important 
role in the prevention of sepsis by (polysaccharide capsuled) bacteria through T-cell 
independent processes.[44] DS children have higher morbidity and mortality of 
bacterial sepsis in comparison to age-matched individuals in their first years of life. 
[45] Further research on B-cell development needs to be performed to answer the 
question whether natural effector B-lymphocytes are indeed affected in DS. 
 The B-lymphocyte proliferation and differentiation and immunoglobulin-profile 
in DS is different from that in young non-DS children with recurrent respiratory tract 
infections. In them, repeated antigen responses lead to an increased pool of B-memory 
subpopulations resulting from multiple consecutive germinal center reactions.[46] 
These children often have low IgA and IgG2 serum levels, but do not have B-lympho-
cytopenia or hypergammaglobulinemia.[47] Most of these children appear to have a 
slower peripheral B-cell maturation, without an apparent immunodeficiency after 
infancy. 
 The question remains whether decreased and altered B-lymphocyte subpopulations 
in combination with a hypergammaglobulinemia in Down syndrome are a true 
reflection of intrinsic B-cell defects. Another explanation would be a disturbed helper- 
T-lymphocyte interaction leading to a skewed control of peripheral B-lymphocyte 
maturation and development through impaired SHM and class switching. 
Vaccination responses
The distribution of B-lymphocyte subpopulations in Down syndrome is reminiscent of 
the situation found in a subgroup of common variable immunodeficiency disorder 
(CVID) patients who suffer from recurrent infections and autoimmune diseases as 
well. CVID is a heterogeneous group of B cell disorders in combination with decreased 
Igs and deficient antibody response to protein (T-cell dependent) and polysaccharide 
(T-cell independent) antigens.[48-51] Different types of vaccination were used in this 
thesis as a model to study these different T-cell immune response pathways in order 
to get more insight into T- and B-lymphocyte functional capacity and communication 
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in DS, in comparison with different patient groups with well-known T- or B-lymphocyte 
defects. 
 In chapter 6 antibody levels and avidity were tested in 22 DS children after TT 
booster vaccination at 4 and 9 years of age. Non-DS children with decreased numbers 
of helper-T-lymphocytes such as children with DiGeorge syndrome [52] or HIV-1 
infection [53, 54] mount a protective response but with lower mean IgG anti-TT-anti-
body titers. DS children produced protective anti-TT antibody titers in both age groups. 
However, post-booster vaccination anti-TT-antibody titers and IgG1-avidity (most 
dominant IgG produced after TT) in the 4-year-old children with DS were significantly 
lower. After booster vaccination at 9 years of age, DS children reached anti-TT-anti-
body total IgG within the adult reference range, but IgG1-avidity was still significantly 
decreased. Lower post-TT avidity despite repeated booster doses suggests a subtle 
selection problem of memory B-lymphocytes within the germinal centers in DS. Such 
selection problems can occur through intrinsic B-lymphocyte defects or through an 
impaired interaction between Th and B-lymphocytes.
 In chapter 7 we determined the haemagglutination-inhibition (HI) titer after two 
doses of influenza A/H1N1 vaccination in 48 DS children. According to the 
WHO-definition of correlate for protection (HI titer ≥1:40), 92% of DS children reach 
protective levels after vaccination. However, this HI cut-off value has not been studied 
for influenza A/H1N1 vaccination in children. Pre-vaccination data from the available 
literature show that up to 30% of healthy children reach a HI titer of ≥1:40 without a 
known history of previous influenza A/H1N1 vaccination or active influenza A/H1N1 
infection. The recently proposed new cut-off value to predict the conventional 50% 
clinical protection rate in children, ≥1:110[55], is reached in only 27% of our DS cases. If 
this HI cut-off value is applicable, our results would further support a T-lymphocyte or 
T-B-interaction problem in DS.
 Others have described impaired immunity in terms of cytokine and antibody 
response in DS in research based upon protein-prototype vaccinations such as 
influenza, hepatitis B and tetanus as well.[56, 57] 
 In chapter 8 MenC polysaccharide specific (MenC/PS) antibody titers after a 
single MenC vaccination were tested in 19 DS children. All DS children reached 
protective levels. However, in comparison to healthy adults MenC/PS antibody titers 
were lower, despite the fact that 9 DS children showed hypergammaglobulinemia. 
Our data show that protein conjugation does not fully overcome the impaired antibody 
production to this polysaccharide antigen in DS. 
 In chapter 9 we determined anti-pneumococcal serotype antibody titers 
(quantitative test) and opsonophagocytosis (qualitative test) after a combined 
scheme of PCV7 (2x) and PPV23 (1x) in 18 DS subjects between 6 and 24 years of age. 
The results show adequate serotype-specific antibody titers when using both the 





























≥1.0µg/ml for prevention of mucosal infection in response to most conjugated and 
unconjugated serotypes tested. DS subjects showed lower responses to serotypes 7F, 
9N and 12F in comparison to healthy individuals, however. Opsonophagocytosis 
activity as measured against pneumococcal serotypes 9N, 19F and 23F was normal. 
We conclude that these DS subjects do not have a defect in the anti-polysaccharide 
antibody response.
 The adequate response to unconjugated pneumococcal serotypes requires 
mature B-lymphocytes and therefore argues against severe B-lymphocyte problems 
or specific anti-polysaccharide antibody deficiency (SPAD) [47] in Down syndrome 
subjects. The adequate antibody titer after TT-booster in combination with an 
adequate pneumococcal vaccination antibody response as seen in our Down syndrome 
subjects are clearly different from CVID patients, despite their apparent clinical 
resemblance with recurrent infections, auto-immune phenomena and malignancies, 
and immunological resemblance with altered memory B-lymphocyte subpopulations.
 Overall, the vaccination studies performed in part 2 show protective post- 
vaccination antibody levels (using current protective cut-off values) in DS, although the 
qualitative and quantitative antibody responses differ per vaccination and subject. 
The pattern of vaccination response in DS is not comparable with the pattern seen in 
severe T-, or B-lymphocyte defects, but subtle impairments of the selection process of 
memory B-lymphocytes within germinal centers of lymph nodes do seem to occur. 
Immunosenescence?
With normal ageing, fewer B-lymphocytes are produced in the bone marrow, and 
thymic involution with low output of naive lymphocytes ensues.[58, 59] At first sight, 
the DS profile seems to fit precocious immunosenescence (chapter 2), because altered 
thymic anatomy and decreased naive B- and T-lymphocytes occur both in DS and 
normal ageing.  
 However, alterations of the T- and B-lymphocyte compartment in DS are present 
from the very beginning: newborns and fetuses [60] with DS already show an altered 
thymic anatomy with impaired thymic output [61] and lower TREC counts [43] as well 
as low naive B-lymphocytes[60] and lower kappa-deleting recombination excision 
circles (KREC) counts. [43]  
 Decreased output of naive B- and T-lymphocytes is mirrored in ageing individuals 
by an increase in effector and memory B, Th and Tc numbers. The lymphocyte pool fills 
up with specific oligoclonal memory T and B-lymphocytes, mainly memory helper (Th) 
T-lymphocytes, terminally differentiated cytotoxic (TD Tc) T-lymphocytes and more 
restricted TCR-γδ Tc and Th with less diversity.[62-65] The lymphocyte pool becomes 
more experienced but less flexible, and the cells show a more restricted repertoire and 
reduced proliferative response. We did not find an early shift towards these oligoclonal 
memory T-lymphocyte subsets (chapter 4) or an early expansion towards memo-
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ry-B-lymphocytes (chapter 5). Serum immunoglobulin levels remain stable during 
normal ageing, but in DS a profound hypergammaglobulinemia develops from around 
3 years of age onwards. 
 With normal ageing, decreased output and functional deficiency of the T- and 
B-lymphocyte pool hampers the adaptive immune response to both T-cell dependent 
and independent vaccinations.[58] Quantitative antibody responses become lower, 
decline faster and the affinity of the antibodies is diminished [58, 66-69], especially in 
response to polysaccharide vaccines. [66]  Our data show that DS subjects respond 
with adequate opsonophagocytosis assay titers to serotype 19F and 23F after repeated 
conjugated pneumococcal vaccinations (chapter 9). 
 The clinical profile with higher rates of infections, malignancies and auto- 
i mmune disease occur both in DS and normal ageing.[70-73] However, the pattern is 
different: DS subjects mainly show higher frequencies of hypothyroidism[72], celiac 
disease[74] and diabetes mellitus type 1[75]  as opposed to elderly subjects with 
increased occurrence of e.g. diabetes mellitus type 2 and rheumatoid arthritis.[76] 
Malignancies in DS are mainly haematological in contrast to elderly who show an 
increase in non-haematological malignancies as well.[77] So, immunosenescence 
does not seem to be an issue in DS. 
Down syndrome: a syndromic immunodeficiency
Down syndrome is the most common chromosomal abnormality in humans. The 
prevalence of Down syndrome in the Netherlands is higher nowadays than during the 
80s and 90s.[97] Early diagnosis and treatment of congenital heart defects has further 
decreased mortality in the first years of life in Down syndrome subjects.[98, 99] But 
despite all health care improvements, the clinical profile of infections, autoimmune 
diseases and haematological malignancies still causes high morbidity and mortality in 
Down syndrome. 
 In this thesis we show that it is unlikely that early immunosenescence explains 
the immunological alterations in DS. Parallels in clinical profile, antibody response to 
vaccination and T- and B-lymphocyte subpopulations between DS and specific 
immuno deficiencies such as DiGeorge syndrome (DGS) and common variable 
immuno deficiency disorders (CVID) exist, however, there are also obvious differences. 
We conclude that Down syndrome subjects have a unique profile of a mild combined 
intrinsic T- and B-cell immunodeficiency.
 Awareness of and more research on this unique syndromic immunodeficiency is 
important for early recognition of immunodeficiency and immunodysregulation in 






























This thesis has provided more insight into the DS immune system, but many questions 
remain. Most studies performed in DS regarding lymphocyte subpopulations and 
function, including our own, are cross-sectional in nature. A large longitudinal cohort 
study with DS newborns and healthy non-DS controls would enable correlation of 
immune alterations with the clinical picture in DS. 
 Based on our data and current knowledge, we cannot determine whether the 
problem in communication between Th and B cells in DS is based upon inadequate Th 
help to B-lymphocytes or upon the incapacity of B-lymphocytes to respond to Th help, 
or both.[38, 78] Systematic analysis of antigen-presentation and processing by 
B-lymphocytes and of the processes influencing the choices made in somatic 
hypermutation and class switch recombination could shed further light on this issue. 
Recent new insights regarding the immunological synapse between antigen-present-
ing cells (APCs)[79] and B-lymphocytes and between B-Th[80] would be interesting to 
study in DS as well. Also, T-lymphocyte selection processes in the thymus can be 
influenced by defective or altered network connections within the immunological 
synapse between APC and thymocytes. Earlier reports found an increased expression 
of cell adhesion molecules in thymic epithelia and thymocytes[81], but with decreased 
T-lymphocyte adhesion to ICAM-1 in another study in DS subjects.[82]
 The immune system has to walk a fine line to preserve the integrity of the body: 
it has to produce an adequate immune response to non-self without inducing immune 
reaction with damage to self. The higher frequencies of autoimmune diseases (e.g. 
celiac disease, diabetes mellitus, thyroid disease) and lymphoproliferation (e.g. 
leukemia) point toward immune dysregulation in DS.[83] Insight in the mechanism 
causing autoimmunity in DS is limited. To our current knowledge, environmental 
triggers are needed for the development of autoimmune disease. Especially infections 
have been implicated in the onset and promotion of autoimmunity.[84, 85] The 
continuous infectious pressure put on the DS immune system due to their anatomic 
and functional respiratory tract abnormalities could thus play a role. Non-DS 
publications highlight the increased incidence of autoimmunity in partial as opposed 
to severe T-cell immunodeficiencies. This might be caused by reduced effectiveness of 
communication between thymocytes and epithelial cells due to disordered thymic mi-
croarchitecture, altering the efficiency of central tolerance.[86] This central tolerance 
is achieved by a process called negative selection: T-cells with too high affinity to 
self-peptide presented on MHC undergo apoptosis in the thymus. These self-peptides 
are tissue-specific self-antigens from different parts of the human body, their 
expression on thymic epithelial cells is controlled by AIRE (autoimmune regulator). A 
recent study on the thymus transcriptome showed significant hypoexpression of 
more than 400 genes related to cell division and immunity in young DS subjects 
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including AIRE.[87] Lack of gaining adequate central tolerance can result in multiple 
organ-specific autoimmune disorders, but it does not lead to an increased allergy rate. 
Indeed, DS subjects have increased organ-specific autoimmune disorders, and a 
decreased allergy rate. So, it is tempting to speculate that thymic hypofunction with 
altered T-lymphocyte development and interaction (including inadequate central 
tolerance) leads to autoimmunity in DS. 
 From a clinical perspective, it is interesting to speculate whether aggressive 
treatment and/or prevention (e.g. ENT interventions, vaccinations, antibiotics) of 
respiratory tract infections in the first years of life will positively influence the 
development of the DS immune system. But also whether decrease of respiratory 
tract infections can lead to improvements in cognitive, motor and speech development 
[102], achieving a higher quality of life for children with DS. 
 Genetic predisposition can influence the sensitivity for actual development of 
autoimmune diseases and malignancies. Genetic studies on DS provide interesting 
insight. DS is not a monogenic disorder, but a consequence of an extra (critical part of) 
chromosome 21.[88] However, contrary to common belief of 150% genetic 
overexpression of chromosome 21 in all DS organs, different expression of chromosome 
21 genes has been described depending on tissue and cell type.[89] 
 Besides, genome-wide expression analysis in DS revealed that hundreds of genes 
related to immune function not located on chromosome 21 appear to be dysregulated 
as well, demonstrating the pervasive effects of trisomy 21 on the whole genome.
[90-93] A typical example from earlier publications are somatic mutations in the 
GATA1 gene (X-chromosome) leading to transient leukemoid reactions in the neonatal 
period in Down syndrome.[94, 95] Somatic mutations in the JAK2 gene (chrosomome 
9) are associated with acute lymphoblastic leukemia in DS. Additional complexities 
may exist due to epigenetic changes that may act differently for DS in general and for 
specific organs.[96] These genetic studies further support our hypothesis that DS 
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Dit proefschrift beschrijft het onderzoek dat gedaan is naar het afweersysteem bij 
kinderen met downsyndroom. Downsyndroom is de meest voorkomende chromo - 
somale afwijking; het wordt veroorzaakt door een extra – 3e – chromosoom 21 (de 
zogenaamde ‘trisomie’ 21). Ieder jaar worden er in Nederland circa 245 kinderen met 
downsyndroom geboren. Zij worden vaak begeleid door een vast team van 
hulpverleners op speciale Down-poliklinieken volgens een landelijk protocol. 
 Kinderen met downsyndroom hebben typische uiterlijke kenmerken met onder 
andere een platte neusbrug, epicanthus plooien (opvallende plooien langs de 
binnenste ooghoeken), een uitstekende tong, kleine oren en een korte nek. Zij hebben 
vaak een viervingerhandlijn en een sandal gap (extra grote ruimte tussen de grote 
teen en de tweede teen). Daarnaast hebben zij een kleine lengte, verlaagde 
spierspanning (hypotonie) en een verschillende mate van ontwikkelingsachterstand 
(mentale retardatie). Ongeveer 50% van de kinderen met downsyndroom heeft een 
aangeboren hartafwijking. Kinderen met downsyndroom hebben een andere 
anatomie van het KNO-gebied: bijvoorbeeld een vernauwde gehoorgang en een 
kleinere en anders aangelegde buis van Eustachius. Kinderen met downsyndroom 
hebben meer speekselvloed, last van zuurbranden (gastro-oesofagale reflux) en ook 
in de onderste luchtwegen kunnen anatomische veranderingen aanwezig zijn.
 Met name in de eerste levensjaren hebben kinderen met downsyndroom veel 
luchtweginfecties. Complicaties door luchtweginfecties zijn de belangrijkste oorzaak 
van overlijden in alle leeftijdsgroepen bij downsyndroom, ondanks alle verbeteringen in de 
zorg voor deze groep. De veranderde anatomie van het KNO-gebied en de lagere 
luchtwegen, een lagere spierspanning en gastro-oesofagale reflux met micro- 
aspiraties worden vaak als oorzaak voor de verhoogde infectiegevoeligheid 
aangewezen. Maar afwijkingen in het afweersysteem zouden ook kunnen bijdragen 
aan het optreden van (ernstige) infecties. Als kinderen met downsyndroom ouder 
worden zie je dat andere aandoeningen, zoals autoimmuunziekten en leukemie, vaker 
voorkomen. Bij autoimmuunziekten valt het lichaam de eigen cellen aan. Voorbeelden 
zijn suikerziekte (diabetes mellitus type 1, DM1), glutenintolerantie (coeliakie) en 
schildklierproblemen. Bij leukemie ontaarden gewone bloedcellen kwaadaardig. Dit 
kan wijzen op een ontregeld afweersysteem omdat normaliter het afweersysteem dit 
ondervangt. Er lijkt bij downsyndroom sprake te zijn van een combinatie van meer in-
fectieproblemen en daarnaast van immuundysregulatie met meer autoimmuunziek-
ten en leukemie. Deze trias wordt ook gezien bij mensen met bekende aangeboren 
afweerziekten en ook bij normale veroudering (waarbij het afweersysteem ook 
minder gaat functioneren).
 In het verleden is al onderzoek gedaan naar het afweersysteem bij downsyndroom. 
Omdat ongeveer de helft van de kinderen met downsyndroom een hartafwijking 
heeft, worden veel jonge kinderen met downsyndroom in het eerste levensjaar 
geopereerd. Tijdens deze operaties viel het op dat de thymus – het belangrijkste 
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afweerorgaan voor T-lymfocyten productie - er anders uit zag. Bij downsyndroom is 
daarom in het verleden met name verder gekeken naar de afwijkingen die werden 
gevonden in de thymus en in de T-lymfocyten. De afwijkende anatomie van de thymus 
in combinatie met de veranderingen binnen de T-lymfocyten, naast het vaker 
voorkomen van dementie op jonge leeftijd leken het beste te passen bij vervroegde 
veroudering. Er werd geconcludeerd dat de veranderingen die bij downsyndroom in 
het afweersysteem werden gevonden het directe gevolg van die vervroegde 
veroudering waren. Inmiddels zijn de onderzoekstechnieken verder ontwikkeld en zijn 
er nieuwe inzichten in hoe het afweersysteem werkt. We hebben daarom opnieuw 
onderzoek verricht naar T-lymfocyten en hebben ook de B-lymfocyten en de kwaliteit 
van de afweerreactie bij kinderen met downsyndroom in kaart gebracht. Onze vraag 
was hoe het verworven afweersysteem bij downsyndroom is opgebouwd en of dit 
leidt tot een afweerprobleem dat vergelijkbaar is met bekende aangeboren afweer-
stoornissen. Verder willen we weten of de eerder voorgestelde theorie aangaande 
vervroegde veroudering van het afweersysteem bij kinderen met downsyndroom 
klopt.
 Bij normale veroudering van het verworven afweersysteem verwacht je 
verminderde aanmaak van nieuwe B- en T-lymfocyten in respectievelijk het beenmerg 
en de thymus. De productie van naïeve lymfocyten neemt af met het ouder worden 
en eerdere generaties zijn grotendeels uitgerijpt tot effector en geheugenpopulaties 
met een beperkt repertoire. Het systeem kan zich niet meer zo flexibel aanpassen en 
vermeerderen in reactie op het binnendringen van (nieuwe) ziekteverwekkers. De 
antistoffen geproduceerd door B-lymfocyten wijzigen met de leeftijd niet qua 
hoeveelheid, maar ze zijn wel vaak van een slechtere kwaliteit. Dit wordt veroorzaakt 
door het beperktere repertoire van de B-lymfocyten als gevolg van eenzijdige (klonale) 
uitgroei en minder goede hulp van helper-T-lymfocyten. Dit leidt tot een slechtere 
antistof-respons op vaccinaties en een toename van infecties, maligniteiten en auto-
immuunziekten met het rijpen der jaren. 
 Het promotieonderzoek bestaat uit twee delen: in Deel 1 wordt gekeken naar de 
samenstelling van het verworven afweersysteem bij downsyndroom: de B-lymfocyten 
en de T-lymfocyten. Deel 2 van het proefschrift gaat over de functionele kwaliteit van 
het verworven afweersysteem bij downsyndroom, getest door middel van vaccinatie 
en de reactie hierop (vaccinatierespons). De resultaten in deze thesis nopen ons 
vraagtekens te zetten bij de hypothese van vervroegde veroudering van het verworven 

















Deel 1: lymfocytensubpopulaties 
In hoofdstuk 2 wordt als inleiding een overzicht gegeven van eerdere publicaties en 
hypotheses over het afweersysteem bij downsyndroom. In hoofdstuk 3 wordt het 
verworven afweersysteem bij downsyndroom vergeleken met het verworven 
afweersysteem bij normale veroudering en bij zeldzame ziektes waarvan bekend is 
dat er sprake is van vervroegde veroudering. Bij downsyndroom wordt al vanaf de 
geboorte een afwijkende anatomie van de thymus gezien en lagere absolute aantallen 
naïeve T- en B-lymfocyten met lagere aantallen nieuwe T-lymfocyten die recent de 
thymus hebben verlaten. Er wordt geen antigeen-gedreven uitbreiding gezien van 
effector- en geheugen-lymfocyten met afname van de naïeve lymfocyten, zoals bij 
veroudering. Het klinische beeld van toegenomen maligniteiten, autoimmuunziekten 
en infecties bij downsyndroom lijkt weliswaar op dat van ouderen, maar er zijn wel 
duidelijke verschillen. Bij downsyndroom worden vooral auto-immuunziekten zoals 
coeliakie en DM1 gezien en maligniteiten zoals acute lymfatische en myeloïde 
leukemie, een patroon dat duidelijk anders is dan bij (vervroegde) veroudering. 
 In hoofdstuk 4 zijn de T-lymfocytensubpopulaties bestudeerd. Vijfennegentig 
kinderen met downsyndroom werden geïncludeerd en vergeleken met leeftijdsgeno-
ten. Zowel helper-T als cytotoxische T-lymfocyten zijn verlaagd aanwezig vanaf de 
geboorte bij downsyndroom. De enorme expansie van naïeve T-lymfocyten die bij 
kinderen zonder downsyndroom wordt gezien, zien we niet terug in ons cohort van 
kinderen met downsyndroom; vermoedelijk blijft het repertoire van de cellen door de 
verminderd doorgemaakte expansie beperkt. De absolute aantallen cytotoxische-T-
lymfocyten laten een herstel zien richting leeftijd gerelateerde referentiewaarden na 
de eerste levensjaren, maar dit wordt vooral veroorzaakt doordat de expansie afneemt 
bij de leeftijdsgenoten. De aantallen helper-T-lymfocyten blijven laag. Dit alles wijst 
op een aangeboren anders functioneren van het T-lymfocytaire compartiment bij 
downsyndroom. 
 Door herhaald contact met antigenen rijpen de aanwezige T-lymfocyten verder 
uit, waardoor het afweersysteem minder flexibel wordt in het maken van een 
adequate afweerreactie op nieuwe bacteriën en virussen. Bij het ouder worden is dat 
duidelijk te zien: helper-T-geheugenlymfocyten, terminaal gedifferentieerde (TD) cy-
totoxische-T-lymfocyten en T-lymfocyten met nog weinig flexibiliteit voor aanpassing 
van de T-cel afhankelijke afweerreactie krijgen de overhand. Bij kinderen met 
downsyndroom vonden we juist geen verhoogde aantallen van deze subpopulaties, 
hetgeen tegen de hypothese van vervroegde veroudering van het afweersysteem bij 
downsyndroom pleit. 
 Het cytomegalievirus (CMV) is een virus dat cytotoxische-T-lymfocyten activeert 
en uit laat rijpen richting terminaal gedifferentieerde cytotoxische-T-lymfocyten. Het 
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aantal TD cytotoxische-T-lymfocyten dat bij contact met CMV wordt aangemaakt is 
een maat voor de kwaliteit van de T-lymfocyten functie, zo blijkt uit eerder onderzoek. 
Patiënten met een infectie met humaan immunodeficiëntie virus (HIV) maken 
bijvoorbeeld in reactie op CMV veel meer TD cytotoxische-T-lymfocyten aan dan 
gezonde mensen. Bij de kinderen die bewezen contact hadden gehad met CMV in 
onze groep met downsyndroom vonden we absolute aantallen TD cytotoxische-T-
lymfocyten die vergelijkbaar waren met gezonde kinderen en lagere aantallen dan bij 
kinderen met HIV of kinderen met afweer-onderdrukkende medicatie. Deze resultaten 
wijzen erop dat er hooguit een milde stoornis in de functie van T-lymfocyten is bij 
downsyndroom.
 In hoofdstuk 5 worden de B-lymfocytensubpopulaties en immuunglobulinen 
(IgG, IgA, IgM; IgG-subklassen) bij de 95 kinderen met downsyndroom beschreven. De 
meest opvallende bevinding is dat de B-lymfocyten verlaagd zijn in alle leeftijdscate-
gorieën. Ondanks deze persisterende B-lymfocytopenie wordt juist een toename van 
de immuunglobulinenproductie gezien. Vanaf de leeftijd van drie jaar is sprake van 
verhoogde immuunglobulinesubklassen IgG1 en IgG3 met verlaagde waarden van IgG2 
en IgG4. Bij veroudering verandert de hoeveelheid immuunglobulinen doorgaans niet, 
maar de kwaliteit neemt wel af. 
 Daarnaast vonden wij een afwijkende verdeling van de perifere B-lymfocyten-
subpopulaties. Er zijn verlaagde aantallen CD27+, CD21high en CD23+ B-lymfocyten. 
Dit patroon wordt ook gezien bij een subgroep van patiënten met de afweerstoornis 
CVID (common variable immunodeficiency). Bij CVID is sprake van een verlaagd IgG in 
combinatie met een verlaagd IgA en/of IgM en een gestoorde antistofrespons. De 
patiënten hebben last van recidiverende luchtweginfecties met vaak permanente 
schade aan de lagere luchtwegen tot gevolg, en een verhoogde kans op maligniteiten 
en autoimmuunziekten. Hoewel dit lijkt op het klinische beeld bij downsyndroom is bij 
CVID juist sprake van verlaagde immuunglobulinen en niet van verhoogde immuun-
globulinen zoals bij downsyndroom. 
Deel 2: vaccinatieresponsen
Het verworven afweersysteem gebruikt twee verschillende routes om een adequate 
afweerrespons te maken tegen antigenen, de T-cel afhankelijke en T-cel onafhankelijke 
route. In dit proefschrift zijn vaccinaties als model gebruikt om deze verschillende 
routes van het verworven afweersysteem te testen. 
 Met de eiwit-antigenen tetanus toxoid en influenza A/H1N1 (“Mexicaanse griep”) 
wordt de T-cel afhankelijke route getest. Bij herhaaldelijke blootstelling aan eenzelfde 
antigeen zoals een herhaalde vaccinatie met tetanus toxoid-vaccin, verwacht je 
activatie van geselecteerde geheugen B-lymfocyten die antistoffen met hoge aviditeit 
(bindingskracht) produceren. Kinderen zonder downsyndroom die een probleem 
















syndroom) laten een verminderde hoeveelheid antistofproductie zien na herhaalde 
tetanus toxoid-vaccinatie en na Mexicaanse griep-vaccinatie. In geval van ernstige T-
lymfocytstoornissen zie je zelfs een afwezige antistofrespons, maar dat is bij 
downsyndroom niet het geval.
 Met de pneumokokken-vaccinatie Pneumo-23, test je de T-cel onafhankelijke 
route. Dit vaccin bestaat uit polysachariden (suikermoleculen) zonder eiwit-anti-
genen. Hiervoor zijn ervaren, meer gerijpte B-lymfocyten nodig omdat ze geen hulp 
kunnen krijgen van T-lymfocyten. Bij ernstige B-lymfocytdefecten zie je dan ook een 
afwezige antistofrespons tegen polysachariden. Bij CVID is zowel de antistofrespons 
na zo’n pneumokokkenvaccinatie als na herhaalde tetanus toxoid-vaccinatie verlaagd.
Met meningokokken serotype C (MenC) vaccinatie en met de heptavalente pneumo-
kokken-vaccinatie (Prevenar) wordt de respons op een eiwit-suiker combinatie middels 
de T-cel afhankelijke route getest. Door een stuk eiwit (conjugaat) toe te voegen aan 
een polysacharide (suiker)- vaccin krijgt de B-lymfocyt toch weer hulp van de helper- 
T-lymfocyt, mits de B-lymfocyt het stuk eiwit op de juiste wijze kan verwerken en 
presenteren aan de helper-T-lymfocyt. 
 In hoofdstuk 6 worden de hoeveelheid antistoffen en hun aviditeit (bindings-
kracht) na herhaalde tetanus toxoid-vaccinatie getest bij 22 kinderen met down - 
syndroom rond de leeftijd van 4 en 9 jaar conform het Nederlandse Rijksvaccinatie-
programma. Bij kinderen met downsyndroom wordt bij 4 en 9 jaar een beschermende 
antistoftiter gevonden. Bij 4 jaar is de hoeveelheid antistoffen (IgG en IgG-subklassen) 
lager dan bij kinderen zonder downsyndroom, bij 9 jaar is de hoeveelheid antistoffen 
gelijk. De hoeveelheid antistof verbetert dus bij herhaalde vaccinatie met tetanus 
toxoid. Desondanks is de bindingskracht van deze antistoffen bij 9 jaar nog steeds 
lager bij kinderen met downsyndroom. 
 In hoofdstuk 7 wordt gekeken naar de hemaglutinatie-inhibitie (HI-) titer na twee 
doses van influenza A/H1N1 vaccinatie bij 48 kinderen met downsyndroom. De oude 
WHO-definitie van bescherming (namelijk het halen van een HI-titer van ≥1:40) wordt 
door 92% van de gevaccineerde kinderen met downsyndroom gehaald, een nieuw 
voorgesteld afkappunt (nl HI-titer van ≥1:110) voor gezonde kinderen wordt door 
slechts 27% van de kinderen met downsyndroom gehaald. Bij een ernstig T-lymfocy-
tendefect zou je een falende antistof-respons verwachten. De kinderen met 
downsyndroom laten zien dat ze wel op dit vaccin kunnen reageren, maar met een 
lagere antistof-respons. 
 In hoofdstuk 8 wordt bij 19 kinderen met downsyndroom na eenmalige 
geconjugeerde meningococcen C (MenC-) vaccinatie gekeken naar de specifieke anti-
stof-titers. De antistofrespons na MenC-vaccinatie was adequaat bij de geteste groep 
met downsyndroom, maar lijkt wel minder lang stand te houden. Of dit klinische 
consequenties heeft is niet duidelijk omdat cijfers over de incidentie van hersenvlies-
ontsteking en de oorzakelijke ziekteverwekkers specifiek voor downsyndroom ontbreken. 
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 In hoofdstuk 9 wordt gekeken naar de specifieke antistof-respons na een 
gecombineerd schema van tweemaal geconjugeerd (Prevenar, T-cel afhankelijk) en 
eenmaal ongeconjugeerd (Pneumo-23, T-cel onafhankelijke afweerreactie) pneumo-
kokkenvaccin bij 18 individuen met downsyndroom ouder dan 5 jaar. Hiervoor is de 
hoogte van antistoffen tegen verschillende pneumokokken-serotypen (stukken 
suikerkapsel) uit de vaccinaties gemeten. Daarnaast werd een zogenaamde 
 opsonisatiefagocytose test gedaan voor 3 pneumokokken-serotypes. Dit is een test 
die de kwaliteit van de antistoffen kan meten, dat wil zeggen hoe goed de antistoffen 
vastplakken aan de stukken pneumokok en er voor kunnen zorgen dat andere witte 
bloedcellen (fagocyten) de pneumokok kunnen herkennen en kunnen doden. De 
groep met downsyndroom reageert adequaat op de geteste geconjugeerde en 
 ongeconjugeerde pneumokokken-serotypes, zowel qua specifieke antistoftiters als 
qua opsonisatie. De adequate antistofrespons na ongeconjugeerde pneumokokken- 
vaccinatie bij downsyndroom past niet bij een ernstig primair B-lymfocyten- 
defect, omdat zij voor deze T-cel onafhankelijke afweerreactie blijkbaar voldoende 
ontwikkelde B-lymfocyten hebben. Ouderen hebben vaak een slechtere afweerrespons 
op  pneumokokken- vaccinaties met lagere antistofkwaliteit. De afweerrespons bij down- 
syndroom is echter wel goed en niet vergelijkbaar met die van ouderen. In combinatie 
met voldoende antistofrespons na tetanus toxoid-vaccinatie is de vaccinatie-respons 
bij downsyndroom ook niet vergelijkbaar met die bij CVID patiënten. 
 De uitgevoerde vaccinatie-studies laten zien dat veelal een zogenaamde 
‘beschermende antistoftiter’ wordt opgebouwd, maar dat de kwaliteit en kwantiteit 
van de antistoffen wel wisselend is.
CONCLUSIE
Bij downsyndroom is het verworven afweersysteem al vanaf de geboorte aangedaan. 
Kinderen met downsyndroom beginnen al met lagere aantallen B- en T-lymfocyten. 
Het gebrek aan cellen wordt niet opgevuld met bepaalde geheugencellen zoals je ziet 
bij veroudering. Er treed geen goed herstel van de aantallen B- en Th-lymfocyten op. 
Onze resultaten passen niet bij de theorie van vervroegde veroudering van het 
afweersysteem bij downsyndroom. In combinatie met het klinische beeld van 
frequente infecties lijkt dit het meest in de richting te wijzen van een intrinsiek 
afweerprobleem. Het meer voorkomen van autoimmuunziekten en leukemie in 
combinatie met de verhoogde immuunglobulinen vanaf de leeftijd van drie jaar 
suggereert tevens immuundysregulatie. 
 Het patroon van afweerreacties na de verschillende typen van vaccinaties bij 
kinderen met downsyndroom is niet vergelijkbaar met die van vervroegde veroudering 
van het afweersysteem. Ook is er geen sprake van een ernstig B- of T-lymfocyten 
















B-lymfocyten waardoor je soms lagere of minder goede antistoffen krijgt na de T-cel 
afhankelijke vaccinaties. Op basis van de gevonden verschillen in vaccinatierespons 
lijkt er een, weliswaar mild, probleem te zijn in de samenwerking en communicatie 
tussen de B- en T-lymfocyten. Bij welk van de twee de oorzaak van de slechtere 
samenwerking moet worden gezocht, is nog niet duidelijk.
  Dit leidt tot een nieuwe hypothese: mensen met downsyndroom hebben een 
intrinsieke afweerstoornis met een gecombineerd mild T- en B-lymfocyten probleem. 
Dit afweerprofiel is niet vergelijkbaar met bekende afweerstoornissen of versnelde 
veroudering, maar uniek voor downsyndroom.
 Niet alle mensen met downsyndroom hebben evenveel last van deze afweerpro-
blemen. Maar downsyndroom is wel de meest voorkomende chromosomale 
aandoening in Nederland en de trends van de afgelopen jaren wijzen ook niet op een 
daling van het aantal pasgeborenen met downsyndroom in Nederland. Daarbij zorgen 
de infecties, de autoimmuunziekten en de vormen van leukemie bij mensen met 
downsyndroom voor veel ziektelast en vroegtijdig overlijden. Het is dus zaak dat 
iedereen die met mensen met downsyndroom werkt kennis van zaken heeft over deze 
specifieke down-problematiek en deze tijdig kan herkennen en behandelen. Op deze 
manier kunnen wij als dokters onze bijdrage leveren aan de verbetering van de 
kwaliteit van leven voor mensen met downsyndroom.
AANBEVELINGEN VOOR TOEKOMSTIG ONDERZOEK
Wat is er nodig voor toekomstig onderzoek? We weten nog heel veel niet. Met name 
is het moeilijk te voorspellen bij welke kinderen met downsyndroom je problemen 
kunt verwachten door veranderingen in het afweersysteem. Welke kinderen binnen 
deze groep hebben een verhoogde kans op leukemie? Hoe wordt de kwaliteit van 
leven op de lange termijn (bijvoorbeeld spraak-taal, motorische en geestelijke 
ontwikkeling) bij deze groep beïnvloed door het optreden van infecties en autoim-
muunziekten zoals schildklierproblemen en suikerziekte? En waar zit de fout in de 
samenwerking tussen de B- en de T-lymfocyten: meer bij de B-, meer bij de T-lymfocyt 
of bij beiden? En kunnen we door gerichte vaccinaties, het voorkomen van (luchtweg-)
infecties, maar ook bijvoorbeeld door langdurige borstvoeding, de ongunstige 
veranderingen in het afweersysteem en de klinische gevolgen daarvan voorkomen?
 Momenteel wordt door onze onderzoeksgroep verder onderzoek gedaan naar de 
ontwikkeling van B-lymfocyten, lange termijn consequenties van infecties op kwaliteit 
van leven en wordt geprobeerd duidelijker te krijgen hoe veel vaker kinderen met 
downsyndroom ziek zijn in vergelijking tot hun leeftijdsgenoten zonder down -
syndroom. Ook is er een landelijk DownteamOnderzoeksConsortium (DOC) opgericht 
om gezamenlijk op te trekken om de kwaliteit van zorg voor mensen met down- 
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Ad-REF        Reference values from healthy adults
ADHS Antibody diluted human serum
AMC Age-matched control
BD Becton Dickinson
CD Cluster of differentiation
CMV cytomegalovirus 
CSR Class switch recombination
CVID Common variable immunodeficiency disorders
DGS DiGeorge syndrome
DS Down syndrome
DSCAM Down syndrome cell adhesion molecule
ELISA  Enzyme-linked immunosorbent assay
ENT Ear-nose-throat
FACS     Fluorescence-activated cell sorting
FI Fold Increase
FITC      Fluorescein isothiocyanate
GALT Gut-associated lymphoid tissue
GMT Geometric mean titer
HBsAg Hepatitis B surface antigen
HI Hemagglutination-inhibition
HIV Human immunodeficiency virus




IPD         Invasive pneumococcal disease
KREC  kappa-deleting recombination excision circles
LFA-1 Lymphocyte function-associated antigen-1
MAb Monoclonal antibodies
MALT Mucosa-associated lymphoid tissue
MenC  Meningococcal serogroup C conjugate vaccine
MFI        Mean fluorescence intensity
NK Natural killer
OPA       Opsonophagocytosis assay




PI  Phagocytosis index    
PPV-23  23-valent pneumococcal polysaccharide vaccine
RPMI     Roswell Park Memorial Institute medium
RTE Recent thymic emigrants
SHM Somatic hypermutation
SPAD    Specific anti-polysaccharide antibody deficiency
Tc Cytotoxic T
TD         T-cell dependent
Th Helper-T
TI         T-cell independent
TNF Tumour necrosis factor
TREC T-cell-receptor excision circle
TT Tetanus Toxoid
